Transcriptional Regulation of Soluble Guanylyl Cyclase by Hampson, Ashling
Technological University Dublin 
ARROW@TU Dublin 
Masters Science 
2009-01-01 
Transcriptional Regulation of Soluble Guanylyl Cyclase 
Ashling Hampson 
Technological University Dublin 
Follow this and additional works at: https://arrow.tudublin.ie/scienmas 
 Part of the Biology Commons 
Recommended Citation 
Hampson, A. (2009). Transcriptional Regulation of Soluble Guanylyl Cyclase. Masters dissertation. 
Technological University Dublin. doi:10.21427/D7BG7S 
This Theses, Masters is brought to you for free and open 
access by the Science at ARROW@TU Dublin. It has been 
accepted for inclusion in Masters by an authorized 
administrator of ARROW@TU Dublin. For more 
information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License 
  
 
Transcriptional Regulation of Soluble 
Guanylyl Cyclase 
 
Ashling Hampson B.Sc. (Hons) 
Postgraduate Diploma  
in Biomedical Science 
2009 
 
 
 
School of Biological Sciences, 
Dublin Institute of Technology, 
Kevin St., 
Dublin 8. 
 
 
In conjunction with FAS Science Challenge Internship programme 
at the Brown Institute, University of Texas, Houston, Texas. 
 
                          
1 
 
TABLE OF CONTENTS 
 
           Page 
Abstract            4-5 
Declaration            6 
Acknowledgements           7 
List of Abbreviations           8-10 
Index of Figures          11-15 
Index of Tables           16 
 
1.0 Introduction          17 
1.1. NO discovery          17-18 
1.2. NO pathway          18-19 
1.3. Nitric oxide synthase isoforms        21-22 
1.4. Blood Vessel Physiology         22-24 
1.5. NO normal function         24-25 
1.6. Nobel Prize in Physiology or Medicine 1998      25-26 
1.7. Derangement of NO levels in vascular disease      26-28 
1.8. Role of subunits of sGC and their functions      28-31 
1.9. Pathophysiological effects on sGC regulation      31-34 
1.10. Splice Variants of sGC and previous work carried out     35-41 
 
2.0 Aims           42 
 
3. Materials and Methods         43 
3.1. Materials           43 
3.1.1. Cell culture reagents         43 
3.1.2. RNA extraction materials        44 
3.1.3. QPCR materials         44-46 
3.1.4. Western Blotting materials        46-47 
3.1.5. Splice variant materials        48-50 
2 
 
            Page 
3.1.6 Equipment          50-51 
3.2. Methods           52 
3.2.1. Culture of endothelial and human vascular smooth muscle cells    52 
3.2.2. Stimulation of cells with cytokines        53 
3.2.3. Harvesting of cells and extraction of RNA and protein    53 
3.2.4. RNA purification         54 
3.2.5. Reverse Transcription PCR        54-55 
 
3.3. QPCR on HAOECs and HAOSMCs       56 
3.3.1. Preparation of  plasmid standard curve      56 
3.3.2. Ligation           56 
3.3.3. Transformation          56 
3.3.4. Miniprep (DNA Extraction)        56-57 
3.3.5. Restriction Digests         57 
3.3.6. Determination of Plasmid DNA Concentration     58 
3.3.7. QPCR on primary cell samples       59 
 
3.4. Western blotting         60 
3.4.1. Western blotting on BE2 and Sf9 cell lysates to determine the antibody  60 
           dilution for sGC detection 
3.4.1.1. BE2 cells and Sf9 cell lysates       60-61 
3.4.1.2. Antibodies used for detection of α1 and β1 subunits in BE2 and    62-63 
              Sf9 lysates 
3.4.1.3. Bradford assay on BE2 cells for protein determination    63 
3.4.1.4. Gel set-up, transfer and blocking       63-64 
3.4.1.5. Antibody addition and membrane development     64-65 
3.4.2. Western blotting on HAOECs and HAOSMCs     65 
3.4.2.1. Endothelial and smooth muscle cell preparation for Western blotting  65-66 
3.4.2.2. Performing Western blotting on primary cells     66 
 
3 
 
                                  Page 
3.5. Splice Variant work                  67-85 
     
3.6. Data Analysis                   85 
 
4.0. Results                    86 
4.1. Culture of primary cells                  86-87 
4.2. RT-PCR                    88-90 
4.3. Plasmid standard curve results                 91 
4.3.1. Spectrophotometer results                 91-92 
4.3.2. Plasmid standard curve electrophoresis and restriction digest             93-94 
4.3.3. QPCR of standard curves                  94-100 
4.4. QPCR on human vascular smooth muscle cells              101-105 
4.5. QPCR data on endothelial cells                105-119 
4.6. Antibody experiments to detect α1 and β1 sGC in BE2 and Sf9                111 
        cell lysates 
4.6.1. Antibody experiments to detect α1 sGC in BE2 and Sf9 cell lysates           111-117 
4.6.2. Antibody experiments to detect β1 sGC in BE2 and Sf9 cell lysates             117-120 
4.7. Bradford Assays                  120-123 
4.8. Westerns blotting results for endothelial cells              123-129 
4.9. Westerns results for smooth muscle cells                         130-133 
4.10. Splice variant work                 134-147 
 
5.0. Discussion                  148-154 
 
6.0. Conclusions                  155 
 
7.0. References                             156-165 
 
4 
 
Abstract 
 
Each year cardiovascular disease causes over 4.3 million deaths in Europe and is the 
cause of nearly one in three deaths in the US.  Nitric oxide (NO) is a toxic atmospheric 
gas which exists in tissues as a biological product of mammalian cells. It has been used to 
manage cardiovascular disease for over a century and to this day remains an important 
treatment option in cardiovascular medicine. NO is produced by many cells in the body 
including vascular endothelial cells. Because of its importance in vascular function, 
abnormal production of NO, which occurs in different disease states, can adversely affect 
blood flow and other vascular functions.  
NO binds to the haem moiety of the enzyme soluble guanylyl cyclase (sGC) 
which is found in vascular smooth muscle cells and most other cells of the body. NO 
diffuses from vascular endothelial cells into the vascular smooth muscle cells adjacent to 
the endothelium where it binds to and activates sGC. sGC is a heterodimer composed of 
two different subunits: α and β. The structure of sGC consists of a haem-containing 
regulatory domain, formed by N-terminal portions of both subunits, and a catalytic 
domain formed by the C-terminal half of both subunits. The N-terminal regions of α and 
β subunits are often referred to as the regulatory domain of the enzyme. Several isoforms 
of these subunits have been described: α1 and α2 and β1, β2 and β3. The heterodimer α1β1 
is practically present in all tissues studied.  
In response to NO binding, sGC catalyses the conversion of guanosine-5′-
triphosphate (GTP) to cGMP. cGMP is an intracellular messenger and acts on several 
cGMP-regulated receptor proteins, such as cGMP-stimulated protein kinases, cGMP-
regulated phosphodiesterases (PDEs), and cGMP-gated ion channels which subsequently 
leads to vasorelaxation. Expression levels of sGC have been found altered in several 
models of cardiovascular disease however the mechanisms behind these alterations 
remain largely unknown. Several extracellular regulators such as inflammatory cytokines 
have been shown to affect sGC steady state levels. The regulation of sGC expression is 
unquestionably important to support cardiovascular function.  
 The main objectives of this project were to study the effects of selected 
inflammatory cytokine stimulation on levels of sGC in human endothelial and smooth 
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muscle cells. Primary human aortic vascular endothelial (HAOECs) and human aortic 
smooth muscle cells (HAOSMCs) were cultured and treated with the inflammatory 
cytokines GM-CSF and IL-4, to determine the effects they would have on sGC mRNA 
and protein expression. The mRNA level was determined using QPCR and the protein 
was analysed using Western blotting. QPCR results showed that cytokine treatment of 
HAOSMCs increase both of the sGC subunits. The opposite effect was seen in HAOECs, 
with a decrease in subunit mRNA expression being observed. Western blot analysis 
revealed that the level of sGC expression in primary cells is too low to be detected by this 
method, with very little antibody binding to either subunit.  
It has been suggested that alternative splicing of sGC may be an important 
mechanism in its regulation. A307838 is a recently discovered sGC splice form of the β1 
subunit. Based on observations of the importance of sGC alternative splicing, a further 
objective of this project was to clone this splice form into an expression vector for future 
expression and testing in viral vectors.  A307838 was PCR amplified as two separate 
fragments (1 and 2), which were transformed into separate vectors and ligated together in 
one plasmid vector. The ligation of fragment 1 and 2 was successful, however the 
orientation of fragment 1 was not correct by the time this study had finished. Work still 
continues on this splice form.  
 The results from this study identify the effects of GM-CSF and IL-4 on sGC 
regulation in primary cells. Our findings point further to a role of cytokines in the 
regulation and activity of sGC. sGC regulation may be finely tuned, and this regulation 
may play an important part in the understanding of the development of many 
cardiovascular disorders. Considering the importance of sGC function, and reports 
concerning the functional significance of its splice forms, the study of A307838 should 
help us to gain further insights into the regulation of sGC.  
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1.0. Introduction 
 
Heart disease remains the first leading cause of death for both men and women in the 
United States and together with stroke, accounts for almost 40% of all deaths annually. 
Nitric oxide donors in the form of nitrovasodilators have been used to manage 
cardiovascular disease for over a century (Lauder Brunton, 1867) even before the 
mechanism of their action was established. To this day, NO donors remain an important 
treatment option in cardiovascular medicine (Murad, 2006). The primary physiological 
target for NO is soluble guanylyl cyclase (sGC) which is expressed in many tissues 
(Waldman Murad, 1987). In addition to direct activation by NO, sGC function may be 
modulated by changes in expression levels. Expression levels of sGC have been found 
altered in several models of cardiovascular disease, and decreased activity and expression 
has been proposed as one of the mechanisms underlying the development of endothelial 
dysfunction (Melichar et al., 2004; Ruetten et al., 1999; Mulsh et al., 2001). The 
molecular mechanisms responsible for regulation of sGC expression remain largely 
unknown. Several extracellular regulators including cytokines affect sGC levels and these 
changes have been associated with cardiovascular disorders (Filippov et al., 1997; 
Papapetropoulos et al., 1996; Ujiie et al., 1994). Knowing sGC levels are affected by 
cytokines, we aimed to take a closer look at these effects.  
 
 
1.1 NO discovery 
 
Nitric oxide, a toxic atmospheric gas exists in tissues as a biologic product of mammalian 
cells. Its actions are as diverse as the cells which produce it (Furchgott & Zawadzki, 
1980). It is an uncharged free radical compound (Krumenacker et al., 2004) and a 
diffusible messenger which functions as an intercellular signalling molecule in most 
tissues (Roy & Garthwaite, 2006).   
NO was largely viewed as a pollutant released from smokestacks and present in 
automobile exhaust and cigarette smoke (Murad, 2006). It was long believed that the 
biosynthesis of nitrogen oxides was an exclusive function of microorganisms, which are 
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well known for their oxidative or reductive pathways. As early as 1916, it was noted that 
mammals secrete more nitrate in their urine than was present in their diets and in the 
early 1980s, nitrogen oxides were established as normal by-products of mammalian 
metabolism (Dawson & Snyder, 1994).  
 The uncovering of nitric oxide (NO) and the L-arginine-citrulline metabolic 
pathway by which it is formed, represented remarkable and unexpected discoveries in 
biological science.  It had been known for years that endothelial cells release a highly 
labile factor involved in the relaxation of the underlying vascular smooth muscle when 
stimulated by a variety of vasodilator substances such as acetylcholine or bradykinin 
(Furchgott & Zawadzki, 1980). This factor was termed endothelium derived relaxing 
factor (EDRF), of which its structure was not known. Early studies indicated that EDRF 
could be viewed as the endogenous equivalent of the nitrovasodilators or the 
“endogenous nitrate”. It appeared that activation of sGC also mediated the effects of 
EDRF. EDRF was later shown to share a common mechanism of action with NO and 
organic nitrates i.e. by activating sGC and elevating cGMP levels in the vascular smooth 
muscle (Papapetropoulos et al., 1996). A number of groups became convinced that EDRF 
was NO and in 1987 irrefutably published data by Salvador Moncada demonstrated that 
EDRF/NO was generated from the oxidation of the terminal guanidine nitrogen atom(s) 
of the amino acid (Scott-Burden, 1999).   
 
 
1.2 NO pathway 
 
The effects of NO can be summarized into two categorical mechanisms of action: cGMP-
dependent, which involves the production of cGMP following NO activation of sGC, and 
cGMP-independent, which are mediated by reactive nitrogen species that are produced as 
a result of the interaction of NO with oxygen or superoxide radicals (Krumenacker et al., 
2004). Why Nature selected such an unstable and highly reactive diatomic molecule to 
serve such critically important signalling functions is still in question (Poulos, 2006).  
NO acts via a well-characterised NO-cGMP pathway (Steinert et al., 2008), and 
its actions are mostly due to cGMP formation. (Marcondes et al., 2006). The prominent 
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receptor for NO known to date is sGC. Stimulation by NO results in the production of the 
secondary messenger cGMP, which exerts its effects via cGMP-dependent kinases, 
channels, or phosphodiesterases (Friebe et al., 2007). It has been only within the last 20 
years that the complete outline of the NO/cGMP signalling pathway has been understood. 
After the discovery of cAMP in 1958 and the initial elucidation of its role in physiology 
the search for other physiologically relevant cyclic nucleotides began. In 1963, cGMP 
was detected in the urine of rats, several years later guanylate cyclase was found in 
mammalian tissues (Denninger & Marletta, 1999).  
The physiological role of NO depends on its local concentrations as well as 
availability. At low nanomolar concentrations, activation of sGC is the major event 
initiated by NO. The resulting elevation in the intracellular cGMP levels serves as signals 
for regulating diverse cellular and physiological processes. cGMP directly regulates the 
activities of its downstream effectors such as Protein Kinase G (PKG), cyclic nucleotide 
gated channels (CNG) and cyclic nucleotide phosphodiesterases (Fig. 1.2.1). Each of 
these downstream effectors then transmits the signals to an array of intracellular 
signalling molecules (Madhusoodanan & Murad, 2007). These NO-dependent signal 
molecules are associated with a number of important physiological processes including 
smooth muscle relaxation, platelet aggregation, neurotransmission and cellular 
differentiation (Sharina, 2000).  
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Figure 1.2.1 Synthesis of cGMP, downstream intracellular signalling targets modulated 
by cGMP and the role of phosphodiesterases (PDEs) in cGMP breakdown. This pathway 
mediates relaxation of vascular smooth muscle relaxation. Smooth muscle relaxation is in 
part mediated via protein kinase G (PKG) activation, subsequent potassium channel 
opening and reductions in intracellular calcium levels (Ghofrani et al., 2006).  
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1.3. Nitric oxide synthase isoforms 
 
Production and release of NO represents one paracrine/autocrine mechanism coordinating 
energy supply and demand in tissues (Stewart, 2004). NO has been shown to play a key 
role in vascular homeostasis by contributing to the regulation of vascular tone, the 
inhibition of smooth muscle proliferation and the antithrombogenicity of the vascular 
wall (Papapetropoulos, 1996). Much has been discovered about the biology of NO 
through the characterisation of the enzyme that is responsible for its formation in living 
tissues, called nitric oxide synthase (NOS). NOS is a highly regulated enzyme which 
catalyzes the five electron oxidation of L-arginine to citrulline and nitric oxide (NO) 
(White & Marletta, 1992). Three isoforms have been identified in a variety of tissues 
(Friebe, 2007). The classification of the nitric oxide synthases has depended on the 
finding that the enzymes in the brain and vascular endothelium are constitutive and are 
activated by calcium and calmodulin, whereas the enzyme in macrophages is inducible 
and calcium-independent. One of the major functional differences between the isoforms 
of NOS is their need for calcium (Ca2+).  
 Isoform I is constitutively expressed in brain and was first purified from rat and 
porcine cerebellum (Bredt et al., 1990; Schmidt et al., 1990). It is a Ca2+ and calmodulin-
dependent enzyme that is inactive at 100nmol/L Ca2+ and fully active at 500nmol/L 
(Forstermann et al., 1991; Schmidt et al., 1991). This represents typical change in 
intracellular Ca2+ concentrations upon receptor stimulation of excitatory cells such as 
neurons. The enzyme is phosphorylated by Ca2+-calmodulin-dependent protein kinase II, 
protein kinase C, and cyclic AMP-dependent protein kinase (Bredt et al., 1990). It is 
constitutively expressed in neurones and has a molecular weight of 155kDa 
(Papapetropoulos et al., 1996).  
 Endothelial cells constitutively express isoform III (endothelial isoform), which is 
shorter (135kDa) than type I (Papapetropoulos et al 1996). It is also found in other cell 
types, is Ca2+-dependent and is called eNOS. eNOS may be phosphorylated in response 
to various forms of cellular stimulation (Michel et al., 1993; Garcia-Cardena et al., 1996). 
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Isoform II of NO synthase is usually not constitutively expressed but can be 
induced in macrophages and many other cells with bacterial lipopolysaccharide and/or 
cytokines including smooth muscle cells (Steuhr et al., 1991; Hevel et al., 1991, Stewart 
et al 2004). The enzyme is also referred to as iNOS or mac-NOS, and in mouse 
macrophages, calmodulin is found stoichiometrically associated with the enzyme (Steuhr 
et al., 1991). 
 
 
1.4. Blood Vessel Physiology 
 
All arteries have a common pattern of organisation and are made up of similar materials, 
though the proportions vary in different parts of the circulation. The arterial walls are 
well-organised connective tissue structures composed of cells and matrix fibres arranged 
in three tunicae: the intima, the media and the adventitia (Levy & Tedgui, 1999) (Fig. 
1.4.1). The intima is the innermost layer and the surface is covered with a single layer of 
endothelial cells (ECs), which rest on the basement membrane of subendothelial 
microfibrils. The media contains mainly circularly arranged smooth muscle cells and 
collagenous fibrils. The adventitia is composed of collagen fibres and fibroblasts that 
protect the blood vessel and anchor it to surrounding structures (Kemball-Cook et al., 
2005). 
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Figure 1.4.1 Diagram showing a blood vessel and the location of vascular smooth muscle 
cells and endothelial cells. Anatomy overview of a human artery made for PhD project 
(Stijn, 2005).  
 
Blood vessels are therefore composed of two interacting cell types, endothelial 
cells and smooth muscle cells. Endothelial cells form the inner lining of the vessel wall 
and vascular smooth muscle cells envelop the surface of the vascular tube (Bergers & 
Song, 2005).The endothelium is a confluent monolayer of thin, flattened, rhomboid-
shaped cells lining the intimal surface of all blood vessels. Due to its strategic position, it 
is important in the mediation and modulation of smooth muscle activity and 
inflammatory responses within the vessel.  
The endothelial cells regulate smooth muscle cell growth by producing both 
growth promoting factors (oxygen free radicals, angiotensin II) and growth inhibiting 
factors (NO, TGF-β, Prostaglandin I2) (Davies & Hagen, 1993). Endothelial cells have 
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receptors for the cytokines IL-1 and tumour necrosis factor beta (TNF-β). Endothelial 
cells, as well as smooth muscle cells produce cytokines, such as IL-1, IL-6 and IL-8. 
These cells may differentially produce and interact with cytokines, thereby contributing 
to the regulation of inflammatory processes in the vessel wall (Schonbeck, 1995).  
Smooth muscle cells possess a cell body with a prominent nucleus and a small 
amount of cytoplasm with several long processes embracing the endothelium wall. They 
communicate with endothelial cells by direct physical contact and paracrine signalling 
pathways. Gap junctions provide direct connections between them and enable the 
exchange of ions and small molecules (Bergers & Song, 2005; Yamamoto & Suzuki, 
2005).  
 
Endothelial NO diffuses to the smooth muscle cells, where it combines with the 
haem moiety of the sGC enzyme (Ignarro, 1987). This guanylate cyclase is activated by 
NO and increases the intracellular concentration of cyclic guanosine monophosphate 
(cGMP). The resulting rise in cGMP from activation of sGC by NO induces vascular 
smooth muscle relaxation by lowering the intracellular Ca
2+
 concentration (Nimmegeers 
et al, 2007). NO regulates many vascular smooth muscle cell functions, including 
vascular tone, as well as cellular proliferation, apoptosis, migration, relaxation and 
synthesis of extracellular matrix (Takata, 2001).  
 
 
1.5. NO normal function 
 
Studies have implicated NO as a mediator, messenger, or regulator of cell 
function in physiologic states that include vascular tone, platelet function, short- and 
long-term memory, hepatocyte respiratory function, septic shock, and penile erectile 
function (Kuo & Schroeder, 1995). NO functions as a vasodilator and is an important 
mediator of homeostatic processes and host defense mechanisms (Moncada et al., 1991; 
Moncada, 1992). The NO signalling cascade regulates many physiological functions in 
the cardiovascular, neuronal, and gastrointestinal systems (Nimmegeers et al., 2007). NO 
has also emerged as a central participant in the immune response. The potential 
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involvement of NO in both the vascular and cellular process of inflammation was 
suggested from its involvement as an effector molecule of macrophage activity (Wagner 
et al., 1983). 
The continuous release of basal NO keeps the cardiovascular system in a state of 
constant active vasodilation and plays a substantial role in regulating blood flow and 
blood pressure (Nimmegeers et al., 2007). In the gastrointestinal system, evidence 
suggests that NO regulates mucosal blood flow, mucosal protection, hemodynamic 
responses to liver disease, hepatocyte synthetic function, and relaxation of the muscularis 
(Kuo & Schroeder, 1995).  
In the vascular system, NO has been shown to mediate smooth muscle relaxation 
and inhibition of platelet aggregation (Friebe et al., 2007). It does this through the 
secondary messenger cGMP.  
 
 
1.6. Nobel Prize in Physiology or Medicine 1998 
 
On October 12th, 1998, the Nobel Assembly awarded the Nobel Prize in 
Medicine and Physiology to scientists Robert Furchgott, Louis Ignarro and Ferid Murad 
for their discoveries concerning NO as a signalling molecule in the cardiovascular 
system. NO was shown to be produced by the NO synthases with the neuronal (nNOS or 
NOSI) and endothelial NOS (eNOS or NOSIII) being of major importance for the 
production of NO as a signalling molecule (Mergia et al, 2008).   
The idea that a simple gas like NO should, at low concentrations, have very specific 
biological effects was initially hard to accept as it gives rise to nitric acid, and at high 
concentrations this would be lethal to cells. On December 2
nd
 1976 Murad’s laboratory 
managed to generate pure nitric oxide and ventilate it into guanylyl cyclase incubations 
(Murad, 2004). In 1979 Murad showed that guanylyl cyclase is one of the enzymes on 
which NO acts in the nanomolar range. For Murad to show conclusively such a small 
amount of NO exerts so many biological effects was not easy. The difficulty was in 
showing that NO was in fact the active compound, and not some other vasodilatory 
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molecule such as nitroglycerin or nitroprusside.  Work then began on the identification of 
EDRF’s target.  
Establishing the link between cyclic guanosine 3’:5’-monophosohate (GMP), 
organic nitrates (such as nitroglycerin), and NO would bring it all together. It was here 
that Dr. Murad made his important contribution to medicine and physiology. Murad and 
colleagues focused on cGMP and the cyclase enzymes responsible for its production from 
guanosine triphosphate (GTP). His early experiments were carried out on guanylate 
cyclase activation by vasodilators and later on the relaxation of smooth muscle by virtue 
of NO generation. Murad studied the numerous pathways of signal transduction wherein 
the NO-cGMP axis plays a role (Scott-Burden, 1999). 
 
 
1.7. Derangement of NO levels in vascular disease 
 
The importance of NO/cGMP signalling for the maintenance of blood pressure is well 
established (Rees et al, 1989). NO is thought to play a role in the pathway of several 
inflammatory disease states such as arthritis, myocarditis, colitis and other pathological 
conditions such as cancer and diabetes (Krumenacker et al, 2004). Dysfunction of the 
endothelial NO/cGMP signalling pathway contributes to the pathophysiology of a variety 
of cardiovascular disorders (CVD) including hypertenstion, thrombosis, atherosclerosis, 
myocardial infarction and angina pectoris (Nimmegeers et al., 2007). CVD is associated 
with progressive changes in the production of free radicals and radical-derived reactive 
species. NO and superoxide (O2
.
) are the most relevant free radicals in biology. Evidence 
suggests that increased NO and O2
.
 production make a significant contribution to the 
progression of CVD (Turko & Murad , 2002).   
Normally, endothelium-derived NO is one of the key protective mechanisms in 
the vasculature (Melichar et al., 2004). In the vascular and cardiac tissue, NO is 
constitutively produced in modest amounts from L-arginine by eNOS or nNOS (Muller et 
al., 2000). eNOS is activated by mechanical stress such as blood shear-stress and 
stimulation with agonists such as bradykinin. The action of NO as EDRF is important for 
maintaining vascular homeostasis (Kawashima & Yokoyama, 2004). The reversible 
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activation of sGC probably accounts for most of the effect of NO on vascular contraction. 
The activation of sGC and subsequent cGMP accumulation is an important mechanism 
underlying the effect of NO in heart and blood vessels (Muller et al., 2000).  
 Endothelial dysfunction is characterised by a decreased responsiveness to 
endothelium dependent vasodilators. This may result from impaired signalling down-
stream from NO in the vascular smooth muscle (Klob et al, 2000).  Patients who have 
hypertension, diabetes or atherosclerosis often exhibit endothelial dysfunction because 
their blood vessels produce insufficient amounts of NO (Murad, 2006).  
Changes in the mRNA expression levels of sGC subunits have been reported in 
several disease models. In aortic tissue from spontaneously hypertensive rats, the 
vasodilator response to an NO donor was markedly attenuated compared with 
normotensive rats. The detailed analysis of hypertensive animals revealed that α1- and 
β1-sGC mRNA levels, as well as β1-sGC protein levels, were reduced significantly, 
indicating that vasodilator dysfunction is related to the sGC gene expression (Jiang, 
2006). 
 Evidence suggests that chronic exposure to NO decreases sGC enzyme activity by 
decreasing the stability of the mRNAs encoding its subunits and that destabilization of 
sGC subunit mRNAs is dependent on gene transcription and protein synthesis (Filippov 
et al, 1997).  
 
CVD is the leading causes of death in Western societies. Arterial hypertension is one of 
the most important public health problems in the developed world. In arterial 
hypertension models, endothelium-dependent vasodilation is impaired as a result, at least 
in part, by oxidative stress and mRNA and protein levels of both the α1 and β1 subunits of 
sGC and sGC activity being reduced (Evgenov, 2006). Adaptation to hypertension 
promotes morphological changes in the aorta characterised by vessel wall thickening. 
Medial hypertrophy and enhanced levels of various growth factors seem to account for 
this adaptive morphological response (Klob et al, 2000). Atherosclerosis is a major 
risk factor to CVDs such as heart disease and stroke. The pathophysiology of 
atherosclerosis is highly complex, multifactorial and yet to be fully understood, but 
involves endothelial injury (Melichar, 2004; Evgenov, 2006). Atherosclerosis is 
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associated with alterations in NO/cGMP signalling. In early stages of the disease, 
inflammatory and possibly other cells produce reactive oxygen species that scavenge 
vasoprotective NO. In addition to the oxidative stress, expression and activity of enzymes 
downstream to NO formation may also be affected (Melichar, 2004). An impairment of 
endothelium-dependent relaxations is present in atherosclerotic vessels even before 
structural changes occur. All major risk factors for atherosclerosis such as 
hyperlipidemia, diabetes, hypertension and smoking are associated with impaired 
endothelium dependent relaxations. Although the underlying mechanisms of reduced 
endothelium dependent relaxation are multifactorial, its most important cause is a 
derangement of the eNOS/NO pathway, which include reduced activity and expression of 
eNOS. It seems that eNOS normal function inhibits atherogenesis by producing NO 
(Kawashima & Yokoyama, 2004). Vascular dysfunction in atherosclerosis is partly 
attributed to reduced bioavailability of endothelium-derived NO, which is supported by 
the reduced activity and expression of eNOS (Melichar, 2004).  
 
 
1.8. Role of subunits of sGC and their functions 
  
sGC is a member of the guanylyl cyclase family of proteins, which respond to 
various ligands by converting GTP into cGMP. It stands apart from other members of its 
family by the nature of its activating ligand. sGC is activated several hundred fold upon 
exposure to NO produced by nitric-oxide synthase. sGC is the key component of the 
NO/cGMO pathway and is crucial in mediating various physiological effects of NO 
mentioned earlier such as blood vessel relaxation, inhibition of platelet aggregation and 
neurotransmission (Martin et al., 2006). In the absence of NO, sGC exhibits very low 
basal activity. Conformational changes following the binding of NO to haem result in 
marked activation of the enzyme (Madhusoodanan & Murad, 2007). sGC was first 
purified (from lung) in the early 1980s (Poulos, 2006). Since its discovery 30 years ago, 
the biochemical properties of this enzyme have been relatively well characterised 
(Sharina et al., 2003).   
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 The human genome encodes two sGC α-subunit and two sGC β-subunit genes 
(Fitzpatrick DA et al., 2006). The α1 and β1 sGC genes have been localized to the same 
chromosome in rat and human (Sharina et al., 2000).   
It is known that the conversion of guanosine triphosphate (GTP) to cyclic GMP is 
catalyzed by at least two isoenzyme forms of guanylate cyclase, of which the kinetic, 
physiochemical and antigenic properties are quite different (Friebe et al., 2007). pGC 
(particulate soluble guanylyl cyclase) serves as a receptor for atrial natriuretic peptides 
and sGC (soluble guanylyl cyclase) serves as a receptor for gaseous ligands, namely NO 
and carbon monoxide (Evgenov et al., 2006). There are six or more particulate isoforms 
of GC. These are receptor cyclases that are transmembrane proteins with an extracellular 
peptide receptor domain, a short transmembrane domain, and intracellular kinase- like 
and catalytic domains (Murad, 2006). The relative abundance of the soluble and 
particulate enzyme is variable in different tissues and species. Intestinal mucosa and 
retina possess predominantly the particulate isoenzyme, and platelets contain the soluble 
isoenzyme. Tissues such as vascular smooth muscle have both isoenzymes (Murad, 
1986). sGC has been accepted as the most important mediator of NO effects, with the two 
most important being aortic relaxation and platelet inhibition (Friebe, 2007).  
 
sGC is a heterodimer made up of two subunits, α and β (Nimmegeers et al., 2007) 
which are encoded by separated genes (Figure 1.8.1) (Sharina et al., 2007). Two isoforms 
are known to exist, α1β1 and α2 β1, in which the β1 subunit acts as the dimerising partner 
for either α subunit. α subunits in the absence of the β1 subunit do not form dimers and 
are not catalytically active. Theoretically, the association of α and β subunits could give 
rise to at least four different isoforms, but only the α2β1 and α1β1 isoforms are reported to 
be active (Nimmegeers et al., 2007) with α1β1 being the most highly and ubiquitously 
expressed. Human vascular smooth muscle, vascular endothelial cells, cerebral cortex, 
and cerebellum express predominantly α1 β1 subunits (Sharina et al., 2003). 
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Figure 1.8.1 sGC is an obligatory heterodimer composed of α1 and β1 subunits. The β1 
subunit binds the prosthetic haem which is the target for NO.  
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The structure of sGC consists of a haem-containing regulatory domain, formed by 
N-terminal portions of both subunits, and a catalytic domain formed by the C-terminal 
half of both subunits which convert GTP into cGMP (Martin et al., 2003). Because of the 
crucial role in binding haem and providing regulation by NO, the N-terminal regions of α 
and β subunits are often referred to as the regulatory domain of the enzyme. In the 
absence of any activators, the enzyme displays a relatively small activity with a low 
turnover number (Martin et al., 2005). sGC contains only one ferrous pentacoordinated 
haem with the His-105 residue of the β subunit acting as the axial ligand. Binding of NO 
to haem Fe
2+
 and the formation of nitrosyl haem result in the disruption of the axial 
coordinating bond and displacement of iron from the protoporphyrin plane (Martin et al., 
2003) The bond between the haem and a nearby histidine residue breaks, causing a 
conformational change that propagates to the catalytic domain, greatly speeding sGC 
activity and the conversion of GTP into cGMP several hundred fold (Roy & Garthwaite, 
2006).   
 
 
1.9. Pathophysiological effects on sGC regulation 
 
Findings on the activity of putative promoter regions demonstrate different transcriptional 
activity for both subunits, suggesting the potential for finely tuned regulation. The ratio 
of expression levels for both subunits varies in a tissue-dependent manner, suggesting 
that the regulation of expression for these subunits is not tightly coordinated. (Sharina et 
al, 2000).   
The mechanisms by which the soluble or membrane forms of guanylyl cyclase are 
regulated have been explored at both the protein and the gene level (Behrends et al., 
1995). Emerging data indicates that regulation of sGC expression could be an important 
factor in the modulation of sGC activity (Sharina et al., 2003). Evidence suggesting that 
sGC activity is regulated at the protein and mRNA levels has begun to emerge (Sharina et 
al., 2000). Expressional regulation of human sGC α1 and β1 subunit expression is likely to 
play an important role in the pathophysiological regulation of enzyme activity. (Marro et 
al., 2008). The identification and characterisation of human α1 and β1 promoters suggest 
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that these subunits may be targets for regulation by a number of transcription factors that 
play critical roles in a variety of cellular processes (Madhusoodanan & Murad, 2007). 
Exposure of cells to pro-inflammatory cytokines or NO is known to induce changes in 
sGC expression For example, lipopolysaccharide (LPS), interleukin 1β, and NO donors 
cause reduced sGC β1 mRNA expression in pulmonary artery smooth muscle cells 
(Marro et al., 2008).  
 The vasculature, when exposed to inflammatory mediators may be able to adapt 
to elevated NO levels by decreasing sGC. Cytokine-mediated changes in the function of 
other components of the NO-cGMP signal transduction system, such as 
phosphodiesterases and cGMP-dependent protein kinases, may also have important roles 
in regulating vascular responsiveness to NO. Cytokine-induced desensitization of 
vascular responsiveness to NO may represent a homeostatic mechanism preventing 
excessive signaling via cGMP and may serve to limit the vasodilation associated with 
sepsis (Masao et al., 2001). It has been demonstrated that in vivo 17β-Estradiol 
administration differentially affects sGC subunits, increasing α1 levels and reducing β1. 
sGC activity was also dramatically reduced by 17β-Estradiol (Cabilla et al., 2006). It has 
also been observed that exposure of rat pulmonary artery smooth muscle cells to the 
cytokines interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α), induced NOS2 
gene expression and decreased sGC α1- and β1-subunit mRNA levels. Decreased sGC 
subunit mRNA levels were accompanied by decreased α1- and β1-subunit protein 
concentrations and decreased NO-stimulated sGC enzyme activity. These observations 
suggest that cytokines may impair sGC enzyme-specific activity as well as decrease sGC 
subunit protein levels (Masao et al., 2001).  
 A family of glycoprotein molecules, termed colony stimulating factors (CSF), are 
known to control proliferation, maturation and functional activities of granulocytes, 
macrophages and their precursors (Bussolino et al., 1991). GM-CSF is a 23-kDa 
glycoprotein cytokine first characterised for its ability to stimulate progenitor 
haemopoietic cells to proliferate and differentiate into mature granulocytes and 
macrophages. It has been shown to have multiple effects in immune activation and to 
influence mitogenesis, acting in concert with other members of the CSF family as a key 
mediator in inflammation and host defence (Weissen-Plenz et al., 2008). GM-CSF is 
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among the cytokines that modulate the functional status of endothelial cells. It has been 
shown that human endothelial cells derived from umbilical veins have high affinity 
receptors for GM-CSF. After binding to its receptor on human endothelial cells, GM-CSF 
starts sequential events, including a rise of intracellular pH and expression of the c-fos 
proto-oncogene, followed by cell migration and proliferation (Bussolino et al., 1991).   
Evidence implicating GM-CSF as a critical player in vascular processes 
associated with structural remodelling such as arteriogenesis and atherogenesis has been 
steadily mounting. In atherogenesis, multiple processes are affected by GM-CSF. GM-
CSF lowers plasma cholesterol levels in humans and animals. Characteristic expression 
and distribution patterns of GM-CSF arise in human coronary arteries during 
atherogenesis. Recent studies point to a key role of GM-CSF in the cytokine network 
regulating the vascular extracellular matrix. In vitro studies on cultured vascular smooth 
muscle cells revealed that GM-CSF modulates the transcription of type VIII collagen, 
which is a key structural component of the vascular (Weissen-Plenz et al., 2008; 
MacBeath et al., 1996).   
 Much of the regulatory function of T cells is mediated by the secretion of a set of 
potent polypeptides often designated as interleukins (ILs). IL-4 is made in response to 
immunologic recognition, principally, although not exclusively, by CD4
+
 T lymphocytes. 
It mediates much of its action in short range interactions between target cells and IL-4 
producing T cells, and it has a wide range of functions. In vitro analysis has demonstrated 
a wide range of functions of IL-4 on B cells, on T cells, on macrophages, on 
haematopoietic precursor cells, and on stromal cells. The extent of these functions 
remains to be determined. IL-4 mediates its functions by binding to receptors expressed 
on target cells (Paul, 1991).   
 
 The 0.3- and 0.5kb regions upstream of the transcription start sites of sGC are 
optimal for α1 and β1 sGC promoter activity (Marro et al., 2008). Figure 1.9.1 shows the 
sGC α1β1 promoter regions. Activator Protein 1 (AP-1) is a ubiquitous transcription factor 
and a pleiotropic regulator of the inducible expression of many genes that encode 
proteins involved in the modulation of inflammatory and host defense processes. AP-1 
has been shown to alter gene expression in response to growth factors and cytokines 
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(Marks-Konczalik et al., 1998). Previous studies have revealed that Nuclear factor of 
activated T-cells (NFAT) is one of the principal transcription factors regulating basal 
sGC expression (Marro et al., 2008). Cooperation between NFAT and AP-1 transcription 
factors has been demonstrated in the promoter/enhancer region of several genes in 
immune cells (Macian et al., 2001). 
 
 
 
Figure 1.9.1 sGC α1β1 promoter regions on chromosome 4q32 
 
 
 The sGC promoter region contains factors which are known to regulate the 
inducible expression of many genes that encode proteins involved in the modulation of 
inflammatory and host defense processes. We know from the literature that α1 and β1 sGC 
levels and activity are affected by a diverse array of inflammatory conditions, and that 
cytokines play a part in this process. In light of this information, one of the aims of this 
project was to determine the effects two such cytokines (GM-CSF and IL-4) would have 
on sGC.  
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1.10. Splice Variants of sGC and previous work carried out 
 
Very little information is available regarding the role of transcription regulation 
by modulators affecting sGC steady-state mRNA, or protein levels, and this mechanism 
of regulation of sGC remains largely unexplored (Gerassimou et al., 2007). There is 
increasing evidence, supporting the existence of sGC splice forms for α1, α2, β1 and β2 
genes (Sharina et al., 2008). With the strong indications that sGC genes undergo an 
alternative splicing which could potentially have a role in regulating its activity in healthy 
and diseased vascular tissue, we set about to clone one of these splice forms into an 
expression vector to study it further.  
 
Alternative splicing frequently occurs in eukaryotic genes and provides an 
important mechanism for tissue-specific and developmental regulation of gene expression 
(Sharina et al., 2008). Differential RNA splicing can serve to switch an active protein to 
an inactive protein (Behrends et al., 1995). Recently, splicing started to emerge as a 
mechanism essential for cardiovascular function and development. A better 
understanding of the mechanisms modulating intracellular cGMP levels, such as 
regulation of sGC expression, are of high importance (Kalsotra et al., 2008).  It is 
conceivable that a given cell modulates its degree of NO responsiveness by the 
expression of differing amounts of alternative subunits of sGC (Behrends et al., 1995). 
 
In mammals, the alternative splicing for the α2-subunit of sGC generates a 
dominant-negative variant. Splice forms for α1 and α2 subunits have been also 
demonstrated. Recently, a shortened α1 sGC transcript has been found, and its expression 
was correlated with lower sGC activity in several cell lines (Sharina et al., 2008). Several 
transcription factors important for housekeeping α1 and β1 sGC transcription have been 
identified. Recent studies have demonstrated that the exposure of rat aortic smooth 
muscle cells to hydrogen peroxide inhibits α1 sGC promoter activity and α1 steady-state 
mRNA levels (Gerassimou et al., 2007). 
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The wild type transcript of β1 sGC has several Accession Numbers in the NCBI 
database including: NM00857, BC047620, AK315999. AK307838 is a novel β1 sGC 
splice form given the name SH-β1. SH-β1 sGC AK307838 is a 592 amino acid β1 sGC 
protein which was isolated focusing on alternative splicing from the human brain (Isogai 
& Yamamoto, Takao Isogani Reverse Proteomics Research Institute, 2008). Figure 
1.10.1 shows the comparative genomic organization for human β1 and the SH-β1 sGC 
splice form. Blue bars indicate conservative exons. Red bars indicate alternative pieces 
inserted by splicing. As can be seen from the diagram, exon 2’ is specific for SH-β1 and 
exon 10’ has an additional 5’ fragment. The 2’ exon introduces a premature stop codon. 
The SH-β1 open reading frame (ORF) starts with a second Methionine (Met) and is 
restored at the 3’ end of exon 2’. Intron 9, which precedes Intron 10’, has an alternative 
splice acceptor at its 3’ end which is upstream of the canonical one. It introduces an 
additional 125 base pairs at the 5’ end of the exon, which makes exon 10’ longer. This 
additional sequence is an in-frame insertion and encodes 43 unique amino acids in SH-β1. 
 
 
 
Figure 1.10.1. A comparative genomic organization of wild type and splice form 
transcript of β1 sGC  
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A global alignment of protein sequences encoded by wild type mRNA and SH-β1 
mRNA is shown in Figure 1.10.2. The alignment searches for identical sequences and 
differences between the two proteins. If both sequences encode identical proteins, no 
change in protein function is expected. As can be seen from the diagram, there are two 
major differences between canonical β1 sGC and SH-β1 sGC protein. SH-β1 has a 
deletion of 68 amino acids at its N-terminal part of the protein (highlighted in green), and 
a 43 amino acid insertion in the middle of the protein (highlighted in red).  
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Figure 1.10.2. Global alignment of the accepted β1 and SH-β1 sGC proteins. The 
sequence highlighted in green shows a deletion of 68 amino acids at the N-terminal part 
of the protein. The sequence highlighted in red shows a 43 amino acid insertion in the 
middle of the protein (Diagram prepared by and included with permission by Dr. Ira 
Sharina, Dr. Ferid Murad’s laboratory, Unpublished).  
 
 Figure 1.10.3 shows the β1 sGC domain structure and compares it with the protein 
encoded by SH-β1. The N-terminal deletion is located close to the haem-binding domain. 
This indicates that domain function may be affected, and could change NO sensitivity of 
sGC heterodimers composed of the SH-β1 splice form. The 43 amino acid insertion is 
positioned very close to the catalytic domain, which suggests that catalysis might be 
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affected also. Based on this analysis, the laboratory hypothesised that regulation of 
expression of SH-β1 by splicing is a new regulatory mechanism to modulate sGC 
function. It was previously shown that splicing does affect enzymatic properties of sGC 
(Martin et al., 2003).  
 
 
 
 
 
Figure. 1.10.3. Comparative domain organisation of β1 and SH-β1 sGC proteins. Wild 
type β1 sGC is showed on top with the haem-binding domain, dimerisation domain and 
the catalytic domain. Underneath is the SH-β1 sGC splice form which is 25 amino acids 
shorter than the wild type. Wild type domain structure adapted from Zhou et al., 2004; 
Wagner et al., 2005.  
 
Recently, one of the focuses of the Murad laboratory has been to isolate and functionally 
characterise the SH-β1 sGC splice form and to prove its biological significance. The 
initial part of the project was to demonstrate that the splice form was indeed expressed in 
human tissue and cancer lines. Twenty normal human tissue samples were screened for 
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SH-β1 transcript detection. RT-PCR screening was performed on cDNA from the twenty 
human samples. SH-β1 fragment was isolated and its identity was confirmed by 
sequencing. cDNA from twelve human cancer cell lines were also used for analysis, 
which SH-β1 was also isolated from. The primers used were localised in a unique 
sequence of SH-β1 exon 10’. The analysis showed that splice form was differentially 
expressed in normal tissues and cancer lines. This confirmed the hypothesis that 
expression of this variant might be regulated to modulate sGC function, possibly in a 
tissue specific manner. mRNA from cancer lines expressing high levels of the variant 
were used for SH-β1 subcloning.  
 
 The next step was to compare the functional properties of the α1/β1 wild type 
heterodimers and α1/SH-β1 heterodimer. To do this the laboratory planned to over-
express both heterodimers in the Sf9 insect line (as they do not contain endogenous sGC) 
and to use them to determine kinetic constants (Vmax, Km) for wild type and splice form 
by measuring cGMP accumulation. To achieve recombinant expression, the aim was to 
create a Baculovirus containing an ORF of SH-β1. In order to achieve this, two SH-β1 
ORF fragments were to be subcloned into the commercial Baculovirus exchange vector, 
pBacPak8.  
 
 The subcloning strategy is described in figure 1.10.4. The ORF had to be 
separated into two fragments because the wild type and the splice form have identical 
sequences surrounding the start and stop codons, which makes it difficult to PCR amplify 
SH-β1 ORF from start to finish without amplifying the wild type at the same time. The 
primers Sh491 (fr1 3’) and Sh492 (fr2 5’) are located in a unique sequence insertion of 
exon 10’, and will be used to prevent wild type amplification. Stu1 sites will be used as 
linkers to join the two fragments together and to restore SH-β1 ORF, as the Stu1 site is 
located uniquely in the SH-β1 insertion.  
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Figure. 1.10.4. Procedure to insert fragments 1 and 2 into pBacpak8. Human SH-β1 was 
broken into two separate fragments (fragment 1 and fragment 2) using specific primers 
and each fragment was then cloned separately into pBacPak8.  
 
 
43 
 
2.0. Aims 
 
Very little is known about the regulation of the expression of sGC. In this study the aim 
was to learn more about this regulation by analysing the effects of cytokine treatment on 
the mRNA and protein levels of sGC. In order to achieve this, we aimed to: 
 
 Culture smooth muscle and endothelial primary cells successfully and treat them 
with a selection of cytokines.  
 The mRNA levels were to be analysed using QPCR. α1 and β1 sGC plasmid 
standard curves had to be set up to allow us to determine the transcript numbers of 
sGC in cytokine-treated mRNA samples.  
 QPCR was then to be carried out to detect α1 and β1 sGC levels in unstimulated 
and stimulated HAOECs and HAOSMCs.  
 Protein levels of samples were to be tested using Western blot analyses. A panel 
of antibodies for α1 and β1 sGC was to be evaluated first on BE2 and Sf9 cell 
lysates for use in Western blotting on primary cell protein samples. α1 and β1 sGC 
protein levels from HAOECs and HAOSMCs were to be analysed using Western 
blotting. 
 
 
In addition to looking at the effects of cytokine treatment on sGC, we wanted to 
successfully incorporate the sGC splice form A307838 into the plasmid vector pBacPak8 
for future enzymatic and functional assays using viral vectors. To achieve this we aimed 
to: 
 Ligate fragment 1 of A307838 into the plasmid vector pCR-Blunt.  
 In addition to this we aimed to re-isolate fragment 2 from pBacPak8 plasmid 
vector to which it had been previously cloned and to restrict and join fragments 1 
and 2.  
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3.0. Materials and Methods 
 
3.1. Materials 
 
3.1.1. Cell Culture Reagents 
 
 HAOEC grown in Endothelial Cell Growth Medium (Cell Applications Inc, Cat 
No. 211-500 Lot 555, stored at 4ºC, Exp 04/09) 
 HAOSMC grown in Smooth Muscle Cell Growth Medium (Cell Applications Inc, 
Cat No. 311-500 Lot 552, stored at 4ºC, Exp 04/09) 
 Human Aortic Endothelial Cells (HAOEC) and Human Aortic Smooth Muscle 
Cells (HAOSMC) (Cell Applications, Inc, 5820 Oberlin Drive, Suite 101, San 
Diego, CA 92121) 
 Trypsin (Cellgro, Mediatech Inc, Manassas, VA 20109. Trypsin EDTA, IX 0.255 
Trypsin/2.21mM EDTA in HBSS without sodium bicarbonate, calcium and 
magnesium. Porcine Parvovirus Tested, Cat No. 25-053-C1, Lot No. 25053195, 
Exp 07/09, Stored at -5º to -20ºC) 
 Trypan Blue dye (Sigma) 
 Lysis buffer (50mM TrisHCL, 150mM NaCL, 1 mM EDTA, 1% Triton, PI 
cocktail from Sigma, 50µl/1.5ml) 
 Recombinant Human Granulocyte Macrophage Colony Stimulating factor (GM-
CSF) (5µg eBioscience, Cat No. 14-8339, 10ng/µl, diluted in 500µl PBS+BSA 
1%) 
 Recombinant Human Interleukin 4 (IL-4) (2µg, eBioscience, Cat No. 14-8049, 
10ng/µl, diluted in 500µl PBS+BSA 1%) 
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3.1.2. RNA extraction materials 
 
 RNAqueous Phenol-free total RNA Isolation Kit. Ambion Inc-The RNA 
Company, Cat No. AM1912, Lot No. 0804010, 2130 Woodward St, Austen, TX 
78744.  
 Agarose (Sigma A5093, 100g, Batch #038K00011, EC 232-731-8, 1g in 100mls) 
 Quick-Load 2-Log DNA Ladder (New England Biolabs, #N0469S, 100µg/ml, 
1.25mls, Lot 0060812, Assay 12/08, Exp 12/10) 
 Gel Loading Dye 6X (New England Biolabs, #B7021S, 1.5mls, Lot 0010811, Exp 
11/11).  
 
 
3.1.3. QPCR materials 
 
      RT-PCR Reagents 
 10X RT Buffer (4319981) 
 25X dNTP (100mM, Lot No. 0810098, Part No. 362271)  
 10X RT Random Primers (Part No. 4319979, Lot No. 0810140) 
 RT Enzyme (multi-scribe, Part No. 4319983, Lot No. 0811074) 
 DEPC H20 
 
      Ligation 
 10X Buffer for T4 DNA Ligase with 10mM ATP (#B02025, NE Biolabs, Lot 
0010806) 
 T4 DNA Ligase (M02025, NE Biplabs, 0.05mls, 400,000 U/ml, Lot 0920805, 
Exo 05/10) 
 1.2M NaCL 
 
      Transformation 
 SOC Medium (Invitrogen, Lot No. 313531, Cat No. 15544-034) 
 Competent Cells (E Coli, Invitrogen) 
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 Kanamycin plates (1000X) 
 
    
 Colony Selection 
 LB Broth, Buncen Burner 
 Conical Flask, Kanamycin (1000X) 
 Forceps 
 filtered tips 
 Culture Test tubes.  
 
      Miniprep 
 QIAprep Spin Miniprep Kit (250), Cat. No. 27106, Lot No. 42477737 
 
      Restriction Digest 
 EcoR1 (New England Biolabs, R0101S, Lot 0320808, Exp. 08/10, 20,000 U/ml) 
 EcoR1 Buffer (New England Biolabs, B0101015, Lot. 0010808, Exp. 08/11) 
 DEPC H20 
 
      QPCR 
 GUCYB3 (Applied Biosystems, Amplicon Length=82, Lot#625260, 250µl 20X 
Mix, Exp 07/2013, 20X) 
 GUCY1B3 (Applied Biosystems, Amplicon Length=100, Lot#487918, Exp 
04/2012, 20X) 
 GAPDH (Lot#642641, Exp 09/2013, 20X) 
 PCR mix (2X, Applied BioSystems) 
 DEPC H20 
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      LB broth/agar 
 20 LB tablets added to 1000mls double distilled deionised water and placed on a 
magnetic stirrer until dissolved. 15g of agar added per litre. Autoclaved.  
 1.5g of Agar was added per 100mls LB broth.  
  
 
  
      Making a molecular weight marker 
 10µl Hind III, 10µl PhiX (New England Biolabs, 500µg/ml, Exp 9/09) 40µl 
loading buffer, 40µl water. Heat at 70 degrees for 5 minutes.  
 
 
3.1.4. Western blotting materials 
 
 
 BE2 cells (kept on ice)  
 Protein Inhibitor A (1000X, Inhibits water soluble inhibitors) 
 Protein Inhibitor B (1000X, Inhibits LMW compounds which are DMSO soluble) 
 BSA stock (5mg/ml) 
 TEA 40mM pH 7.4. 
 Blotto Non-Fat Dry Milk, Santa Cruz Biotechnology SC-2325 Lot No. G1408, 
250g, Santa Cruz Biotechnology, Lot #G1408) 
 Amersham ECL Plus Western Blotting Detection Reagents, GE Healthcare 
(RPN2132, RPN 2133). GE Healthcare, ECL RPN 2132 PL Ren D2006, 
Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA, UK.  
 Sigma N, N, N’, N’-Tetramethlyethyl-enediamine, 99%, T9281-100ml Batch No. 
114K06101 
 Kaleidoscope Prestained Standards, Bio-Rad (Catalog No. 161-0324) 
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 10X TBST+0.1% Tween (1ml tween per 1000mls 10X TBST, 10X TBST made 
up using 100mls 100X TBST+900mls deionised water) 
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Western Buffers 
 
 10X Transfer Buffer (0.25 M Tris, 1.92 M Glycine) 
 Transfer Buffer (100mls 10X Transfer buffer, 200mls methanol, 700mls H2O) 
 10X TBS Buffer (pH 7.6, 12.5g Trizma Base, 60.5g NaCL, 500mls) 
 1x TBST (1X TBS, 0.1% Tween 20, 50mL NaCL (1.5g), 500mls, 50mls 10X 
TBS, 0.5mls Tween, 450mls H2O.  
 Blocking Buffer (100mls 1X TBST, 5g Blotto Milk, microwave, spin, cool on ice) 
 
      SDS/PAGE Gels 
 
 Cell Lysate Buffer (40mM TEA, 0.742g Triethanolamine, HCL (185.52 FW, 
100mls H20) 
 4X Lameli Loading Buffer (5ml Upper buffer, 0.8ml SDS, 4ml glycerol, 
Bromophenol Blue, 1ml 2 beta mecaptoethanol).  
 4X Lower Buffer (1.5M Tris, ).4% SDS, pH 8.8, 91g Trizma Base, 0.4g SDS, 
500mls) 
 4X Upper Buffer (0.5M Tris, 0.4% SDS, pH 6.8, 30g Trizma Base, 2g SDS, 
500mls).  
 10X Running Buffer (0.25M Tris, 1.92 Glycine, 1%SDS, 1L, 30g Trizma Base, 
144g Glycine, 10g SDS (added last), pH not adjusted) 
 8% Upper Gel (6.6mls H20, 3mls 4X Lower Tris Buffer, 2.4mls 29:1 Acrylamide 
Bis (40%), 120µl 10% APS (100%), 12µl TEMED (added last),  
 12% Lower Gel (5.4mls H20, 3mls 4X Lower Tris Buffer, 3.6mls 29:1 
Acrylamide:Bis (40%), 240µl 10% APS (100%), 28µl TEMED, layer of water 
saturated with 1-n-butanol on top of polymerized lower gel). 
 Costar Stripettes, 5mls (4487), 10mls (4488) and 25mls (4489), Corning 
Incorporated, Non-Pyrogenic Serological Pipets, NY 14831)  
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3.1.5. Splice variant materials 
 
       PCR Amplification 
 Pfu (house purified) 
 Pfu 10x Buffer (Stratagen) 
 Primers, 20 uM stocks, custom order (IDT, Integrated DNA Technologies, 
Coralville, IA) sequences designed to cover ORF of SH-b1 sGC splice form and 
based on A307838 sequence 
 
Ligation 
 10X Buffer for T4 DNA Ligase with 10mM ATP (#B02025, NE Biolabs, Lot 
0010806) 
 T4 DNA Ligase (M02025, NE Biolabs, 0.05mls, 400,000 U/ml, Lot 0920805, 
Exp 05/10) 
 1.2M NaCL 
 
Transformation 
 SOC Medium (Invitrogen, Lot No. 313531, Cat No. 15544-034) 
 Competent Cells (E Coli, Invitrogen) 
 Kanamycin plates 
 
    Colony Selection 
 LB Broth, Bunsen Burner 
 Conical Flask,  
 Kanamycin (1000X) 
 Forceps 
 filtered tips 
 Culture Test tube 
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DNA Extraction 
 QIAprep Spin Miniprep Kit (250), Cat. No. 27106, Lot No. 42477737 
 Pure Yield Plasmid Miniprep System (Promega) 
 NucleoSpin Plasmid. Kit (Cat No. 74058810, Lot No. 806/004) (Macherey-
Nagel) 
 
Dephosphorylation 
 Antarctic Phosphastase (M02895, 5,000U/ml, Exp 01/09, Lot 014080L, 0.2mls, 
NE Biolabs). 
 NEBuffer Antarctic Phosphatase (B02895, 10X, 1.5mls, Lot 0707, NE Biolabs).   
 
Band Purification 
 Qiagen QIAquick Gel Extraction Kit (50) 
 
DPN1 Treatment 
 DPN1, New England Biolabs, 20,000U/ml 
 
DNA Precipitation 
 Sodium Acetate (3M) 
 100%v ethanol 
 80% ethanol 
 Nuclease-free water 
 
Ligation Reagents 
 10X Buffer for T4 DNA Ligase with 10mM ATP, #B02025, New England 
BioLabs, 0.5ml, Lot 0010806, Exp. 06/11 
 T4 DNA Ligase, #M02025, New England BioLabs, 400,000 U/ml, 0.05ml, Lot 
0920805, Assay 05/08, Exp. 05/10 
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Dephosphorylation reagents 
 New England BioLabs, NE Buffer Antarctic Phosphatase, B)2895, 10X, 
concentration 1.5ml, Lot 0707 
 New England Biolabs Antarctic Phosphatase , M02895, 5,000 U/ml, Lot 
0140801, 0.2ml, Exp 01/09 
 
 
3.1.6. Equipment 
 
 Thermo Electron Corporation PX2 Thermal Cycler, Labnet Rocker 25 
 Thermo Electron Corporation Forma 3LGP 4500R Centrifuge, Multi-Blok Heater 
No. 2097-1, Lab-Line Instruments, Inc. Designers and Manufacturers, Melrose 
Park, ILL. 
 AquaBath-Barnstead Lab-Line, Cecil CE9500, 9000 Series-Super Aquarius, 
Sharp Carousel 
 Thermolyne-Maxi Mix Plus 
 Thermo Electron Corporation, Forma Series II, Water Jaceted CO2 Incubator, 
HEPA Class 100 
 Thermo Electron Corporation, KeyWrite-D, Jouan, CR3i Multifunction 
Centrifuge 
 Magni Whirl Constant Temperature Bath, Blue M Electronic Company, Blue 
Island, Illinois, USA 
 MicroStar AO Scientific Instruments, CRC Precision Electronics, 8704 
Haverstock Drive, Houston Texas, 77031) 
 SterilchemGARD III Advanceº 
 Falcon Pipet-Aid, Sarstedt-Scre Cap Tube Conical 15ml, 17x120mm 
 Falcon Pipet-Aid Lot 8122088 Exp 2010 05, Sarstedt-Scre Cap Tube Conical 
50ml, 28x114mm Lot 8217087 Exp 2010 08 Sarstedt, Inc. Newton. NC 28658-
0468 
 Posi-Click Tube by Denville, Lot 080912-229 
 Cecil CE9500, 9000 Series, Super Aquarius 
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 Molecular Devices-Emax precision microplate reader 
 Fisher Scientific Isotemp Incubator 
 Sonics Vibra Cell Sonicator  
 Applied Biosystems ABI Prism 7900 HT Sequence Detection System, 200582 
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3.2. Methods 
 
 
3.2.1. Culture of endothelial and human vascular smooth muscle cells 
 
Cell Culture 
Human Aortic Endothelial Cells (HAOEC) and Human Aortic Smooth Muscle Cells 
(HAOSMC) (Cell Applications) were each received in two T25 flasks, both at passage 
three and approximately 60% confluent. HAOEC were grown in Endothelial Cell Growth 
Medium, and HAOSMC were grown in Smooth Muscle Cell Growth Medium according 
to the manufacturer’s recommendations (37ºC, 5% CO2 humidified).   
 
Passaging Cells 
Cells were split when they reached 80-90% confluency. The medium was aspirated and 
3mls of trypsin at room temperature was added to each flask and left for up to four 
minutes, checking cells under the microscope after each minute and gently tapping the 
flask until they began to lift from the base. 3mls of appropriate medium was then added 
to each flask to dilute the trypsin and halt the trypsinisation process. This was followed 
by washing with a further 2mls of medium to ensure all cells had been harvested. Flasks 
were checked microscopically to determine if most of the cells had been removed, and 
rinsed in an additional 2mls of media. Cells were collected into 50ml Universal tubes 
(Sarstedt Inc, Newton NC) and centrifuged at 1100rpm at 4ºC for 5 minutes. The media 
was aspirated, taking care not to remove the pellet which was resuspended in 2mls of 
media. For determination of the total cell count, a 10µl aliquot of the 2ml suspension of 
cells was added to 10µl of Trypan Blue dye and mixed well. A haemocytometer was then 
used to count the total number of cells. The total cell count was then used to determine 
the suspension volume to add to each well.  
 
HAOSMCs were seeded at 6,000/cm
2
, and HAOECs were seeded at 5,000/cm
2
 as 
recommended by the manufacturer. 
 
 
56 
 
Freezing Cells 
100µl of room temperature DMSO was aliquoted into 4 cryovials. Splitting of cells was 
carried out as described. The cell pellet was resuspended in 3600µl serum-free media 
(SFM) and 900µl was added to each cryovial. Cryovials were kept at -70ºC overnight, 
and then transferred to liquid nitrogen the following day. 
  
 
3.2.2. Stimulation of cells with cytokines 
Human recombinant cytokines were received as follows: GM-CSF (5µg/50µl) and IL-4 
(5µg/50µl) (eBiosciences) and were diluted using 1% BSA in PBS (w/v) to a final 
treatment concentration of 10ng/ml and 50ng/ml for GM-CSF and 100ng/ml for IL4. 
Leftover stocks were kept and frozen at -80ºC. HAOSMC and HAOEC cells at passages 
four and five were treated for nine hours with GM-CSF/IL4. Treatment was as follows: 
 
1x 6 wellplate - control (untreated) 
1x 6 wellplate - 10ng/ml GM-added (3µl of 10ng/µl stock) 
1x 6 wellplate - 50ng/ml GM-added (15µl of 10ng/µl stock) 
1x 6 wellplate - 50ng/ml GM (15µl of stock) + 100ng/ml for IL4 (30µl of stock). 
 
 
 
3.2.3. Harvesting of cells and extraction of  RNA and protein 
Three of the wells on each six well plate were harvested for protein lysate analysis and 
the other half for RNA purification. For protein lysates, 200µl of lysis buffer (50mM 
TrisHCL, 150mM NaCL, 1 mM EDTA, 1% Triton, PI cocktail from Sigma, 50µl/1.5ml) 
was added into the top three wells of the six well plates, incubated on ice for 10 minutes 
and scraped by rubber policemen. An additional wash of 50µl of cold lysis buffer was 
carried out for some wells. 400µl of lysis-binding buffer (RNAqueous, Ambion) was 
added to the other three wells containing cells to be used for RNA purification. Samples 
were stored at -20ºC.  
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3.2.4. RNA Purification 
RNA was purified using the RNAqueous Phenol-free total RNA Isolation kit (Ambion 
Inc, Cat #AM1912). Samples had been previously suspended in 400µl lysis solution and 
were thawed on ice. 400µl of ethanol were added and samples were vortexed. The 
suspensions were then gently pipetted into transfer columns, taking care not to pipette 
directly onto the filter. Columns were then spun for 30 seconds at 10,000rpm. The flow-
through was discarded, 700µl of Wash Solution 1 was added to the filter cartridge and 
samples were spun as before. The wash step was repeated using 500µl Wash Solutions 2 
and 3. An additional spin was carried out for 10-30 seconds to ensure the filter was dry 
before it was transferred quickly into a fresh collection tube. 1.5mls of the Elution 
Solution was pre-heated to 70-80ºC and 50µl was added to columns, taking care not to 
touch the filter. Columns were spun for 30 seconds and the elution was repeated using 
20µl of elution solution. 70µl RNA was eluted in total for each sample.   
 
The concentration and purity of the RNA was determined using a spectrophotometer and 
a 1% agarose gel. 5µl of RNA was diluted by a factor of 200 and the absorbance 
measured on the spectrophotometer. 5µl of RNA sample was mixed with 5µl loading 
buffer containing formaldehyde and heated for 2-5 minutes at 70ºC. The samples were 
then run on the gel.  
 
 
3.2.5. Reverse Transcription PCR 
RNA collected from HAOEC and HAOSMC was used for reverse transcription PCR. 
One microgram of total RNA from each sample was reverse transcribed. 10µl of RNA 
was added to 10µl RT-PCR master mix containing: 
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For one sample µl 
10X RT-Buffer 2.00 
25X dNTP (100mM 0.8 
10X RT Random Primers 2.00 
RT Enzyme (multi-scribe) 1.00 
DEPC H20 4.2 
Total 10µl 
Reverse Transcription-PCR reaction for one sample 
 
 
48 samples in total were reverse transcribed in two batches, with 4 non-amplified controls 
(NAC) in each.  
 
 
NAC Controls µl 
10X RT-Buffer 2.00 
25X dNTP (100mM 0.8 
10X RT Random Primers 2.0 
RT Enzyme (multi-scribe) - 
DEPC H20 5.2 
Total 10.0 
Reverse Transcription-PCR reaction for NAC controls 
 
 
 
The Reverse Transcription-PCR conditions were as follows: 
Step 1 Step 2 Step 3 Step 4  
25ºC  37ºC 85ºC 4ºC Temperature  
10 minutes 120 minutes 5 seconds  ∞ Time 
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3.3. QPCR on HAOECs and HAOSMCs 
 
3.3.1. Preparation of plasmid standard curve 
It was necessary to set up a standard curve in order to determine the copy number of sGC 
in each of our samples. pCR-Blunt plasmids containing either alpha or beta target genes 
were diluted such that a standard curve containing a range of copy numbers could be 
prepared.  
 
 
3.3.2. Ligation 
In order to prepare plasmids containing our target genes, our target genes first had to be 
ligated into plasmids. pCR-Blunt was the plasmid used. Previously PCR-amplified α1 and 
β1 sGC were used in the ligations. One ligation was carried out for α1 sGC and one for β1 
sGC. 4µl of PCR product was added to 1µl pCR-Blunt along with 1µl NaCl (1.2M) and 
left on ice for 5 minutes.  
 
 
3.3.3. Transformation 
All solutions were kept on ice. 3µl-5µl of ligation product (α1 sGC and β1 SGC) was 
added to 50µl of competent cells E. Coli. and gently mixed. The transformation was left 
for 20 minutes on ice then heat-shocked for 30 seconds at 42ºC. Cells were immediately 
transferred to ice and incubated with 250µl of SOC medium at 37ºC for one hour. Two 
different volumes of cells were spread on pre-warmed kanamycin plates and incubated 
overnight at 37ºC. Once grown, 10 colonies from the α1 transformation and 10 colonies 
from the β1 transformation were used to inoculate 20 tubes containing 10ml of LB broth 
with kanamycin. Tubes were then incubated overnight at 37ºC.   
 
 
3.3.4. Miniprep (DNA Extraction) 
A miniprep on pCR-Blunt plasmids was carried out using the Qiagen QIAprep Spin 
Miniprep Kit. Overnight cultures were spun at 20 degrees Celsius at 6000 rpm for three 
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minutes. LB supernatant was discarded and pellets were resuspended in 250µl of Buffer 
P1 and transferred to a micro-centrifuge tube. 250µl of Buffer P2 was then added and 
samples were mixed thoroughly 4-6 times. After mixing 350µl of Buffer N3 was added 
and tubes were inverted 4-6 times. Samples were then spun for 10 minutes at 13,000rpm. 
A compact white pellet formed. Supernatants were applied to QIAprep spin columns by 
pipetting then centrifuged for one minute. The flow-through was then discarded. 
Columns were washed twice, the first wash with 500µl Buffer PB and the second with 
750µl Buffer PE with one minute spins in between each step. DNA was then eluted using 
50µl water. 
 
 
3.3.5. Restriction Digests 
A master-mix containing nuclease-free water, EcoR1 Buffer (10X) and EcoR1 enzyme 
was made up. EcoR1 was added last. 10µl of the mastermix was added to 10µl of sample 
and incubated for 1.5 hours at 37ºC. Following incubation, a 5µl aliquot of restriction 
product was run on a 1% agarose gel to ensure both plasmids contained alpha 1 sGC and 
beta 1 sGC. 6X loading dye was added to samples. The gel was then anaylsed under UV 
light using GelDoc apparatus. 
 
The restriction digest was carried out as follows: 
 
Reagent For one sample X5 
DNA 10µl - 
EcoR1 Enzyme 1µl 5µl 
EcoR1 Buffer 2µl 10µl 
H20 7 µl 35µl 
Total 20µl 50µl 
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3.3.6 Determination of Plasmid DNA Concentration 
Once we had ensured that each plasmid contained α1 sGC or β1 sGC, their concentrations 
could be determined. The plasmids were then diluted to prepare two standard curves, one 
for α1 sGC and one for β1 sGC containing known copy numbers of our target genes. 
Plasmids were diluted by a factor of 200 (2µl in 1000µls) measured on a 
spectrophotometer and their corresponding concentrations determined. Their 
concentrations were then used to set-up dilutions on QPCR plates. 
 
The absorbance was multiplied by a factor of 50 to calculate the concentration of the 
DNA in µg/µl. These results were then plotted against the volume and the equation of the 
line determined. The concentration of each plasmid per 1µl was calculated using a 
spectrophotometer. The α1 plasmid contained 5,570 basepairs, and the β1 plasmid 
contained 5357 basepairs. The weight of one molecule of each plasmid was calculated by 
multiplying the number of base pairs by 660 Daltons to give the number of grams per 
each molecule. Next we calculated the weight of  300,000 molecules in 1µl. To know 
how much more concentrated our plasmids were their concentrations were divided by the 
weight of 300,000 molecules in 1µl. For pipetting convenience, we wanted our 300,000 
molecules in 5µl, which meant we needed to further dilute our plasmids by five. 
 
 
pCR Blunt Alpha 1 sGC 0.5µg/µl 28,000X 
Stock Copy Number 
A1 300,000 
B1 30,000 
C1 3,000 
D1 300 
F1 30 
Dilution of plasmid standards 
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3.3.7. QPCR on primary cell samples 
After standards for alpha and beta had been set-up, QPCR could be performed on our 
samples. Each well of the 96 well QPCR plates contained: 
 
QPCR Mastermix µl 
Genes 20X 1 
PCR Mix 2X 10 
Samples 5 
H20 4 
Total 20µl 
 
Three mastermixes were prepared. One for the alpha gene, one for the beta gene and one 
for GAPDH which was used as a loading control to ensure the same amount of DNA was 
loaded for each sample. All cDNA samples were analyzed in triplicate and reagent 
containing no sample was used as a background control. Plates were run on the QPCR 
analyzer (7900 HT Sequence Detection System). QPCR was performed on all 48 cDNA 
samples.  
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3.4. Western Blotting 
 
 
Western blotting is a technique used to detect specific protein in a sample. It uses gel 
electrophoresis to separate denatured protein by the length of their polypeptides. The 
proteins are then transferred to a membrane (PVDF) where they are probed using specific 
antibodies to detect the target protein. The overall purpose of us performing Western blot 
experiments was to detect α1 and β1 sGC in protein samples from our primary cells.  
 
 
3.4.1. Western blotting on BE2 and Sf9 cell lysates to determine the antibody dilution for 
sGC detection.  
 
Westerns were to be performed on primary cell protein samples but as no ideal antibody 
to detect α1 and β1 forms of sGC had been determined, and primary cell samples were 
precious, several antibodies were tested on other proteins containing sGC. Some 
antibodies were new and others had been used previously. Western blots were carried out 
on BE2 cells and on Sf9 cells which contained recombinant alpha and beta sGC.  
 
 
 
3.4.1.1. BE2 and Sf9 cell lysates 
BE2 cells are a neuroblastoma cell line. They are known to express to high levels of sGC 
and are used as controls in Western Blot experiments for the identification of the correct 
band for α1 and β1 sGC. BE2 cells were grown in the laboratory and collected once they 
reached 80% confluency. They were then kept on ice and trypsinised, then washed with 
PBS and spun. The supernatant was aspirated and cells were frozen at -80ºC. 250µl of 
lysis buffer (5mls, 5X) and 5µl Proteinase A and B (1000X, kept on ice) were added to 
BE2 cell pellets and transferred to labeled eppendorfs. Samples were sonicated using a 
medium-sized sonication tip and surrounded by ice to prevent denaturation. Sonication 
was set at 8 pulses every two seconds and 40% amplitude. Samples were then spun at 
14,000g for one hour at 4ºC. A ninety six well plate was prepared to determine the 
protein concentrations of samples before loading them onto a gel. BSA stock (5mg/ml) 
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was diluted with deionised water and used to set up a protein concentration standard 
curve.  
 
Sf9 cells are derived from pupal ovarian tissue of the Fall Armyworm Spodoptera 
frugiperda. The Sf9 cell line is highly susceptible to infection and is commonly used to 
isolate and propagate recombinant baculoviral stocks and to produce recombinant 
proteins. Human recombinant α1β1 sGC was expressed by using the Sf9/baculovirus 
system. Sf9 cells were previously co-infected with baculoviruses expressing 
independently α1 and β1 subunits, and cells were harvested 3 days after infection. After 
harvesting they were then treated in the same manner as the BE2 cells as detailed above.  
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3.4.1.2. Antibodies used for detection of α1 and β1 subunits in BE2 and Sf9 lysates 
 
The following tables list the antibodies tested:  
 
Panel of anti α1 sGC Antibodies used 
 
 Antibody Epitope Dilution 
    
1 9908-1 (First Boost) C-Terminal 1:1000 
2 9908-2 (Second Boost) C-Terminal 1:1000 
3 9908-0 (Trial Sample) C-Terminal 1:1000 
4 9907-1 (First Boost) C-Terminal 1:1000 
5 9908 (C-α new) C-Terminal 1:10 
6 1168-2 (Second Boost) C-Terminal 1:2000 
7 F1168 (company purified) C-Terminal  1:10 
8 1168-1 N-Terminal 1:2000 
9 4096 C-Terminal 1:1000 
10 4096 C-Terminal 1:500 
11 4096 C-Terminal 1:50 
12 5214' (4096) C-Terminal  1:100 
 
Table 3.4.1.2.1. List of α1 sGC antibodies evaluated, detailing the epitope and the dilution 
used  
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Panel of anti β1 sGC Antibodies used 
 
 
Antibody 
 
Epitope 
 
Dilution 
 
1 4843 (affinity purified) C-Terminal 1:1000 
2 0028-2 C-Terminal  1:2000 
3 F0028 (company purified) C-Terminal  1:2000 
4 4843 C-Terminal 1:1000 
 
Table 3.4.1.2.2. List of β1 sGC antibodies evaluated, detailing the epitope and the dilution 
used 
 
 
3.4.1.3. Bradford assay on BE2 cells for protein determination 
Samples were defrosted on ice. 5µl or 20µl of supernatant from each lysate was added to 
the plate and made up to 200µl using deionised water. Samples were then diluted 1:2 to a 
final volume of 100µl in each well. 25µl of Bio-Rad Protein Assay Solution was added 
last. The plate was tapped gently to ensure mixing and read on a spectrophotometer at 
590nm to determine protein concentration.  
 
 
3.4.1.4. Gel set-up, transfer and blocking 
 
Gel set-up 
The lower gel (12mls, 8%) was made using 3mls 4X Lower Tris Buffer, 2.4mls 40% 
acrylamide, 6.6mls H2O, 120µl and 12µl TEMED. Once all reagents had been added, the 
gel was quickly poured into Bio-Rad glass plates. A layer of n-butanol was added over 
the lower gel and gently poured off once it set. Deionised water was used to rinse the top 
of the lower gel. The upper gel (5ml, 5%) was made up using 2mls 4X Upper Tris Buffer, 
1ml 40% acrylamide, 5mls H2O, 80µl APS, and 10µl TEMED and poured into the glass 
plates on top of the lower gel. A comb to create 50µl wells was added to the gel. Once 
both gels were set, glass plates were suspended in running buffer. BE2 lysates were 
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added to wells. Protein lysates were prepared by adding Lameli loading buffer (4X) and 
boiling for five minutes. Different volumes of protein were added depending on the 
results of the Bradford assay and pre-calculated volumes of samples were added to wells. 
15ul of a molecular weight marker was added to the middle well of each gel. Gels were 
run for approximately 2 hours at 100V.  
 
 
Transfer 
After electrophoresis was complete, the gel was opened gently and the upper gel cut off.  
Transfer solution (kept on ice) was poured into a large Pyrex dish. The blotting apparatus 
was set up as follows: negative terminal of blotting cassette, two sponges, three sheets of 
filter paper, gel, membrane (cut to size and dipped briefly in methanol), two sheets of 
filter paper, two sponges, positive terminal of blotting cassette. The cassette was closed 
and placed in the transfer bucket (Bio-Rad Mini-Protean II) in the Pyrex dish which was 
packed with ice and a magnetic stirrer. Frozen water, in universal tubes was added to the 
bucket to maintain the temperature before it was setup in the cold room for transfer for 
1.5 hours. After the transfer, the membrane was removed from the apparatus and was 
ready for the blocking step.  
 
 
Blocking 
Blocking was carried out using 5% dried milk in TBST (w/v, 200mls volume), heated for 
30 seconds and cooled. Prepared blotting solution was poured on the membranes and left 
for 15-30 minutes on an automated rocker (LabNet Rocker 85).   
 
 
3.4.1.5. Antibody addition and membrane development 
 
A total of sixteen antibodies for both α1 and β1 sGC were evaluated: Nine α1 antibodies 
and four β1. The dilutions used ranged from 1:10 to 1:2000, however most antibodies 
were used at a dilution of 1:1000. Most were specific for the C-terminal of either the α1 
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or β1 sGC subunit. Many of the α1 sGC antibodies came from the same rabbit, but were 
purified from different boosts, some being more specific than others. Several blots were 
performed for each antibody. All antibodies were diluted in milk and incubated in trays 
for two hours at room temperature on an automated cell rocker. 
 
 
Membrane Development 
After incubation, the antibody was poured off and the membrane washed three times in 
TBST (1%) (v/v). The secondary antibody (goat anti rabbit, IgG) was prepared in milk 
and diluted 1:6500 (dilution used as a standard in the laboratory) and incubated with 
washed membranes for forty five minutes. Membranes were washed again after 
incubation allowing 5 minutes in between each wash step.  
 
The ECL Western Blotting Detection Reagents kit was used to develop membranes. 2mls 
of this solution was added to the membrane, and left to develop for five minutes. Excess 
reagent was removed and membranes were placed on plastic trays to be developed in the 
dark room. Blots were allowed to develop anywhere from a few seconds, to overnight 
exposure, depending on the protein concentration and the strength of the antibody being 
used.  
 
 
3.4.2. Western blotting on HAOECs and HAOSMCs 
 
3.4.2.1 Endothelial and smooth muscle cell preparation for Western blotting 
Protein lysates from endothelial and smooth muscle cells previously stored at -80˚C were 
defrosted on ice. Once defrosted, proteinase inhibitors A and B (1000X) were added to 
each sample. Samples were then sonicated twice using the smallest tip at a setting of two 
pulses every two seconds at 40% amplitude. Samples were then spun in the cold room for 
ten minutes at 10,000 rpms. The supernatant was removed and placed into 1.5ml 
eppendorf tube. 5µl and 20µl was taken from each sample and the protein concentration 
determined on a ninety six well plate prepared in the same way as for BE2 lysates and 
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recombinant cell proteins. The plate was read on a spectrophotometer to determine the 
protein concentration.  
 
 
3.4.2.2. Performing Western blotting on primary cells 
Now that the antibody evaluation had been carried out using BE2 and Sf9 lysates, our 
primary cell samples were run on Western blots for BE2 and recombinant cell proteins as 
described above.  
 
Secondary Antibody Addition 
Membranes were washed as before. The secondary antibody (goat anti rabbit, IgG) was 
prepared in milk, diluted 1:6500 (standard dilution used in the laboratory routinely) and 
incubated with washed membranes for forty five minutes. Membranes were washed three 
times after the incubation. All TBST was drained from washed membranes before the 
addition of ECL, as described previously.  
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3.5. Splice variant work 
 
The human sGC splice form A307838 has recently been discovered in brain tissue. In this 
project, we aimed to incorporate the full splice form into the plasmid vector pBacPak8 so 
it could then be used in further experiments using viral vectors. A307838 had been 
broken into two fragments: fragment 1 and fragment 2. Fragment 2 had previously been 
ligated to pBacPak8 and needed to be re-joined to fragment 1. To achieve this aim we 
first had to PCR amplify fragment 1 cDNA and ligate it to pCR-Blunt. It was then 
transformed into competent cells, the DNA was extracted and the fragment was re-
isolated using restriction digest. The next step was to ligate it to fragment 2 in pBakPak8 
and to transform it into competent cells. A brief overview of this procedure is shown in 
Figure 3.5.1 below.  
 
 
Figure 3.5.1 Flow-through of procedure to incorporate A307838 in pBacPak8. 
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3.5.1. Fragment 1  
 
PCR Amplification. 
 
Fragment 1 was PCR amplified from cDNA sources including human brain, 
gastric cancer samples and BE2 cells.  Several PCRs were carried out using different 
primers which had been designed previously to amplify the fragment 1 section of human 
β1 sGC A307838 splice form. The PCR procedure was set up as follows:  
 
 
cDNA 2µl 
Pfu 2µl 
Primers 2.5µl (of each) (20 uM) 
10X buffer 5µl 
dNTPs (2.5mM) 4µl 
H2O 32µl 
 
 
Primers used were:   Sh498, Sh499, Sh491 and Sh494. See table 3.5.1 below.  
 
 
Primers Sequence Comments 
Sh 494  5’ AGGATCCATGTTTGGGAAGATGTTTTTCGTC 3’ 
AK307838, Fragment 1, starts with 
Met2, contains BamH1 linker 
Sh 491 5’ ATAGGCCTGGATTCTAGCAGGACATCCTG 3’ 
Subcloning AK307838 ORF, Downstream 
fragment1, Stu I site included 
Sh 498 
5’ AGGATCCAAATGTTTGGGAAGATGTT TTTCGTCTT 
TTG c 3’ 
AK307838, Fragment 1, replacement for 
494, starts with Met2, contains BamH1 
linker 
Sh 499 5’ ATAGGCCTGGATTCTAGCAGGACATCCTGTGTC 3’ 
Subcloning AK307838 ORF, replacement 
for 491, downstream fragment1, Stu I 
site included 
 
Table 3.5.1.1. Primers used to PCR amplify fragment 1 of A307838. Sequences are given 
along with comments on each primer. 
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Ligation 
Non-stick RNase-free 1.5ml Microfuge tubes were used for ligations. 4µl of 
isolated fragment 1 and 1µl of pCR-Blunt (Fig. 3.5.1.12) with activated toperisomerase 
(kept on ice) were added to tubes. 1µl NaCL (1.2M) was also added. Ligation reactions 
were carried out for 5 minutes at room temperature. 
 
Figure 3.5.1.12. Diagram of pCR-Blunt plasmid vector (Invitrogen Life Technologies).  
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LB media preparation 
LB media on which to grow chemically competent E.Coli bacteria was prepared in a 1 
litre container filled with deionised water. 20 LB tablets were added and stirred until 
dissolved. To prepare LB agar plates, 15g of Bacto Agar was added before the flask was 
autoclaved.  
 
Transformation 
Transformation was carried out the same way as previously described. See section 3.3.3.  
 
Colony Selection 
The lid of the LB broth container was flamed before approximately 100mls was added to 
a conical flask. Kanamycin (1000X) was then added. 5mls was then dispensed into 
plastic Culture Test tubes in the presence of an open Bunsen flame. A kanamycin 
selective plate was labelled with a grid and numbered. Using a sterile forceps and a 
pipette tip, up to 20 colonies were selected, touched off the numbered grid plate, and then 
placed in a numbered Culture Test tube. Tubes were then incubated overnight in an 
automated shaker at 37˚C.  
 
Miniprep (DNA Extraction)  
DNA extraction was carried out as described in section 3.3.4. The amount of DNA 
extracted was determined using a 10µl aliquot of DNA samples run on a 1% agarose gel.  
 
DNA Extraction Kit evaluation 
The standard DNA extraction kit used in the lab was made by Qiagen. However during 
the course of this project, the DNA yield from this kit became very low. As a result, two 
new DNA extraction kits were evaluated: The Nucleospin Plasmid kit and the Promega 
Pure Yield Plasmid Miniprep System. 
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NucleoSpin Plasmid. Kit (Cat No. 74058810, Macherey-Nagel, Clontech) 
 
Overnight cultures were spun at 20 degrees Celsius at 6000 rpm for three minutes. LB 
supernatant was discarded and pellets were resuspended in 250µl Buffer A1 and samples 
were mixed thoroughly by gentle piptetting up and down. Samples were then moved to 
NucleoSpin Plasmid Columns, and 250µl of Buffer A2 was added. Tubes were inverted 
6-8 times. Samples were then incubated at room temperature for up to five minutes, or 
until the lysate disappeared. 300µl of Buffer A3 was then added and samples were mixed 
thoroughly by inverting tubes 6-8 times. Tubes were spun for 5 minutes at 11,000 x g at 
room temperature until the supernatant became clear. Plasmid columns were then placed 
into collection tubes (2mls) and the supernatant was decanted into the column by 
pipetting. Tubes were then centrifuged for one minute at 11,000 x g and the flow-through 
was discarded. 600µl of Buffer A4 was added. Tubes were spun as before and the 
supernatant was discarded. The silica membrane in the column was dried by centrifuging 
for two minutes at 11,000 x g and the supernatant discarded. DNA was eluted by placing 
tubes in a clean tube and adding 50µl Buffer AE. Samples were incubated for one minute 
at room temperature and then spun for one minute at 11,000 x g.  
 
 
PureYield
TM
 Plasmid Miniprep System (Promega) 
 
Overnight cultures were spun at 20 degrees Celsius at 6000 rpm for three minutes. LB 
supernatant was discarded and pellets were resuspended in 600µl of TE buffer. 100µl of 
Cell Lysis Buffer was added and tubes were mixed gently by inverting 6 times. The 
solution changed from opaque to clear blue indicating complete lysis. After no more than 
2 minutes, 350µl of cold (4-8ºC) Neutralization Solution was added and mixed 
thoroughly by inverting the tubes. The solution turned yellow when neutralization was 
complete and tubes were inverted another 3 times. Tubes were centrifuged at 13,000 
rpms for 3 minutes. The supernatant was transferred to a PureYield
TM
 Minicolumn which 
was placed into a PureYield
TM
 Collection Tube and centrifuged at 13,000 rpms for 15 
seconds. The flow through was discarded and 200µl of Endotoxin Removal Wash was 
75 
 
added to the Minicolumn and samples were spun as before. 400µl of Column Wash 
solution was added and minicolumns were spun at 13,000rpms for 30seconds. They were 
then transferred to clean 1.5 ml microcentrifuge tubes and 30µl of Elution Buffer was 
added directly to the minicolumn matrix and let stand for one minute. Tubes were then 
spun as before for 15 seconds to elute the plasmid DNA.  
 
Restriction Digests 
Restriction digests were carried out to determine if fragment 1 had been successfully 
ligated to pCR-Blunt (Fig. 3.5.1.1), and  to test for the presence of fragment 2 which had 
already been cloned into the plasmid vector pBacPak8. All restriction digests were 
carried out the same way, the only difference being the NEB buffer, addition of 10X BSA 
and the enzyme/enzymes used. Figure 3.5.1.2 3 shows the common restriction sites used 
to cut pCR-Blunt in order to detect fragment 1. The expected fragment size after various 
restrictions used are shown in figure 3.5.1.34.  
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Figure 3.5.1.23. Restriction sites on pCR-Blunt-fragment1 
 
 
Restriction Enzymes used on Fragment 1 ligated to pCR-Blunt are shown in Figure 7 ??? 
check figure number. 
 
Figure 3.5.1.23 is a representation of the plasmid vector pCR-Blunt containing 
fragment 1. The plasmid is 3.5kb in size and fragment 1 is 1.0kb in size, resulting in a 
plasmid vector 4.5kb in length. Each restriction site that was used during the cloning 
process is shown, including those present inside the fragment.  
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Fig. 3.5.1.34. Length of restriction products of pCR-Blunt-fragment1 when cut with 
different restriction enzymes.  
 
 
 
 
 
 
 
An example of one such restriction digest to test for the presence of the fragment 1 in 
pCR-Blunt was set up as follows: 
 
Reagent For one sample X5 
DNA 10µl - 
EcoR1 Enzyme 1µl 5µl 
EcoR1 Buffer 2µl 10µl 
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H20 7 µl 35µl 
Total 20µl 50µl 
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A master-mix containing nuclease-free water, EcoR1 Buffer (10X) and EcoR1 enzyme 
was made up. The enzyme was added last. 10µl of the mastermix was added to 10µl of 
sample and incubated for 1.5 hours at 37ºC. Following incubation, a 5µl aliquot of 
restriction product was run on a 1% agarose gel. 6X loading dye was added to samples. 
The gel was then analysed under UV light using GelDoc apparatus. 
 
Several restriction digests were carried out on the fragment 1-pCR Blunt product using a 
variety of different restriction enzymes to test for the presence of fragment 1. These 
enzymes were: EcoR1, Spe1, Xho1, BamH1, HindIII, Stu1, Kpn1, Nsi1.  
 
Band Isolation 
Selected bands were cut from 1% agarose gels in the darkroom using UV light. 
As much gel as possible was cut from the fragment, which was placed in an eppendorf 
tube. The QIAquick Gel Extraction Kit was used to purify bands. 500µl of buffer QX1 
was added to the tube. 15µl of beads was then added and mixed well by vortexing. The 
solution became milky and was left for ten minutes at 50ºC, giving it a quick vortex every 
two minutes. It was then spun for one minute at 13,000 rpm.  
The supernatant was aspirated and discarded. The beads were resuspended in 
another 500µl of QX1 buffer and given a quick vortex, before it was spun again and the 
supernatant aspirated. 700µl of PE buffer was then added and the tube spun again and the 
supernatant aspirated as before. This step was repeated using 500µl of PE buffer.  
The pellet at the bottom of the tube was allowed to dry completely after all the 
supernatant had been aspirated. 25µl of nuclease-free water was added to the tube, mixed 
well and incubated for one minute at 50ºC. The tube was re-spun for one more minute 
and the supernatant transferred to a clean eppendorf. An aliquot was run on a 2% agarose 
gel to test for the presence of a band.  
 
Dpn 1 Treatment of Fragment 1 
Dpn 1 is a 4-base cutter with the recognition sequence 5' GATC 3'. It is specific for 
methylated DNA. The purpose of Dpn 1 treatment is to digest away wild type methylated 
DNA, so that the only remaining plasmid is the PCR product. 1µl of DPN was added to 
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10µl of PCR product to purify the fragment and remove methyl groups present in plasmid 
DNA. It was incubated for 1 hour at 37˚C. The DPN was destroyed by heating the sample 
to 80˚C for 20 minutes.  
 
DNA Precipitation 
When low levels of DNA were extracted from our minipreps, DNA precipitation was 
performed to concentrate the DNA and measure it on the spectrophotometer. One tenth 
the DNA volume of sodium acetate (3M), and double the DNA volume of ethanol, was 
added to the DNA. It was then kept -80ºC overnight. The next morning the tube was 
centrifuged at 14,000rpms at 4ºC. A white pellet formed at the bottom of the tube. The 
ethanol was decanted, and 80% ethanol (kept at -20ºC) was added. The tube was then 
spun at 4ºC for 15 minutes at 14,000rpms. This wash step was repeated 3 times. The 
supernatant was discarded and 60µl of nuclease-free water was added. The DNA 
concentration was then measured on the spectrometer (µg/µl).  
 
 
3.5.2.  Fragment 2 
RAGMENT 2 
Figure 3.5.2.15 shows pBacPak8, which was used to clone fragment 2 of the 
splice form A307838. All major restriction sites and the binding sites of the Bac1 and 
Bac2 primers used for sequencing of the plasmid vector are clearly marked. 
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Figure 3.5.2.15. Diagram of the plasmid vector pBacPak8 used to cloned fragment 2 
 
 
Sequencing 
Sequencing of samples was carried out by Lone Star Labs (7501 Fannin, Suite 
740, Houston Tx 77054). 10µl of sample was aliquoted and sent for sequencing.   
 
Designing new Primers 
New primers were designed to correct the Stu1 restriction site. Primers which 
were 15 basepairs upstream of Stu1 and 15 basepairs downstream of the Stu1 site were 
designed. When choosing the sequences for the new primers it was decided that they 
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should begin or end with a C or a G to add more stability. The following primers were 
used: 
 
Upstream Forward primer: Sh503 (primer for mutagenesis to correct Stu1 site in 
pBacPak8-A307-Fr2-plasmid. 
5’ CTGTTTCGTAAAGGCCTTAAAGTACAAACGAC 3’ 
 
Downstream Reverse Primer: Sh504  
3’ GACAAAGCATTTCCGGAAATTTCATGTTTGCTG 5’  
 
Mutagenesis 
A mutagenesis uses primers containing a desired mutation to incorporate a 
mutation into our plasmid DNA. The principle behind a mutagenesis is as follows: 
 Plasmid DNA is denatured and primers containing the desired mutation are 
annealed to the complementary strand. DNA polymerase then uses the plasmid DNA as a 
template to extend the primers. PCR utilises thermostable DNA polymerases, which 
enable the high temperature denaturation of DNA plasmids to create single-stranded 
templates without simultaneously denaturing the polymerase enzyme. In order to remove 
template DNA from the PCR product mixture, the mixture is then treated with Dpn I 
which selectively digests the parent template DNA, leaving only mutant DNA assembled 
in vitro. The nicked vector DNA (containing the desired mutation) is then transformed 
into our competent cells. The cell machinery repairs the nicked DNA, and the repaired 
mutant plasmid can be isolated by miniprep. 
A mutagenesis on pBacPak8-fragment2 was performed using the new primers 
(made up to a concentration of 20µM).  
 
It was carried out as follows: 
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DNA (pBacpak8-fr2)          3µl 
Sh503 (forward primer)      2µl 
Sh504 (reverse primer)       2µl 
10X Pfu buffer                    5µl 
dNTPs (2.5mM)                  4µl 
Pfu (10X)                            4µl 
H2O                                   30µl 
 
Total                                  50µl 
 
 
 
After the initial set-up, the mutagenesis was PCR amplified on the following cycle: 
 
 
Denaturation 
95 ºC - 2 minutes 
94 ºC – 2 minutes 
 
Amplification 
72 ºC – 10 minutes 
60 ºC – 1 minute 
Repeated seventeen times 
 
Elongation 
72 ºC – 20 minutes 
Reaction held at 4 ºC 
 
 
 
 
Dpn 1 Treatment 
Dpn 1 treatment was carried out as previously described in section 3.5. 
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Transformation 
DPN1-treated mutagenesis products (5µl and 2.5µl) were transformed into competent 
cells using the same transformation method used previously. 
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Dephosphorylation 
pBacPak8-fragment2 needed to be dephosphorylated to minimize a self-ligation 
background, before it could be ligated to cut fragment 1. 5’ phosphate was removed from 
linearised pBacPak8-fragment2 so that when fragment 1 was added, pBacpak8–
fragment2 would ligate to fragment 1 and not to itself. By removing the phosphates on 
pBacPak8, self ligation became impossible.  
 
The procedure was carried out as follows:  
 
 
10µl DNA 
2µl Antarctic Phosphatase 
2µl Antarctic Phosphatase 
Buffer 
6µl H2O    
20µl Total 
 
 
 
It was then left for one hour at 37ºC.  
 
 
Restriction Digests 
Many restriction digests were performed on pBacPak8-fragment2 to ensure that the 
fragment had been successfully cloned into the plasmid vector and that all restriction sites 
were correct. Figure 3.5.2.26 shows the restriction sites used to cut pBacPak8 to isolate 
fragment 2 and ensure its correct insertion into the plasmid vector. Different restrictases 
gave different sized fragments. A representation of some of the fragments and their sizes 
are shown in figure 3.5.2.37.  
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Figure.3.5.2.26. Diagram showing Fragment2-pBacPak8. All major restriction sites are 
marked 
 
 
Restriction digests carried out on pBacPak8-fragment2 were: 
1. Sph1, Kpn1 
2. Stu1 (to linearise) 
3. Kpn1 (to linearise)  
4. Not1, Pst 
5. Stu1, Eag1 
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Figure 3.5.2.37. Diagram showing expected fragment/fragments size of pBacPak8 
after various restriction digests.  
 
 
3.5.3. Fragment 1 and Fragment 2 
 
pCR-Blunt-fragment1 and pBacPak8-fragment2 were re-transformed separately using 
sterile techniques previously described into competent E Coli cells and incubated at 37ºC 
overnight to achieve as many colonies as possible, and a high level of DNA of each 
fragment. This DNA was then extracted and run on a 2% agarose gel. pCR-Blunt-
fragment1 was restricted using Stu1 to completely cut fragment 1 from pCR-Blunt (Fig. 
3.5.3.18). The restriction digest was carried out the same way as previous restrictions.  
Figure 3.5.3.214 illustrates the expected fragment sizes when pCR-Blunt, 
containing fragment 1 was cut with Stu1. Assuming correct cutting was achieved, two 
fragments, one 1.0 kilobases in length and the other 3.5 kilobases in length should be 
present.  
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Figure 3.5.3.18. Diagram showing the restriction of pCR-Blunt containing fragment 1 
with Stu1. 
 
pBacPak8-fragment2 had to be linearised in order to ligate it to fragment 1. This 
was achieved by a restriction digest using Stu1, performed in the same manner as 
previous restriction digests. The linearised fragment was 5.5kb in length if it had been cut 
correctly and was ready to be ligated to fragment 1. 
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Figure 3.5.3.29. Diagram showing the restriction of pBacPak8-fragment2 using Stu1.  
 
 
Ligation 
The Stu1 site in pBacPak8-fragment2 had been repaired. Fragment 1 was isolated and 
pBacPak8-fragment2 was linearised. An aliquot of fragment 1 and linearised pBacPak8-
fragment2 were run on a 2% agarose gel to ensure that both fragments were present, had 
been cut and were the correct size. The next step was to ligate fragment 1 and fragment 2 
together. 
 
This ligation was made up of: 2µl of pBacPak8-fragment2 (vector), 1.5µl of 1.5 
10X buffer for T4 DNA ligase, 2µl of T4 DNA ligase and 9.5µl of cut pCR-Blunt-
fragment1 (insert). The total volume was 15µl. The reaction was left for 48 hours in the 
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4ºC cold-room. A transformation was then carried out in the same way as previously 
described, and colonies grown up as before. Other ligations used 1µl of vector (diluted 
1:5), 7µl of fragment 1, 1µl of T4 DNA ligase and 1µl of T4 DNA ligase buffer and the 
reaction kept at room temperature overnight.  
                            
3.6. Data analysis 
Data are presented as means ± standard deviations.  To test for statistical differences 
between mean values, paired t tests were used where appropriate. A value of p < 0.05 was 
accepted as statistically significant. 
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4.0. Results 
 
In this study we aimed to learn more about the regulation of sGC, and the role cytokines 
may play. We carried this out by culturing primary HAOECs and HAOSMCs in a 37ºC, 
5% CO2 humidified incubator. It was hoped that these primary cells would give a more 
true to life picture of sGC regulation than BE2 cells on which experiments had previously 
been carried out. Primary cells were treated with a selection of cytokines. The mRNA 
levels were analysed using QPCR. α1 and β1 sGC plasmid standard curves were set up to 
allow us to determine the transcript numbers of sGC in cytokine-treated mRNA samples. 
QPCR was then carried out to detect α1 and β1 sGC levels in unstimulated and stimulated 
HAOECs and HAOSMCs. Protein levels of samples were tested using Western blot 
analyses. A panel of antibodies for α1 and β1 sGC was evaluated first on BE2 and Sf9 cell 
lysates for use in Western blotting on primary cell protein samples. α1 and β1 sGC protein 
levels from HAOECs and HAOSMCs were then analysed using Western blotting.  
 
 
4.1. Culture of primary cells 
Cell culture proved successful. Cells remained uncontaminated and healthy. Smooth 
muscle cells grew faster than endothelial cells and were harvested at passages 4 and 5. 
Endothelial cells being slower growers were harvested at passages 5 and 6. The 
manufacturers recommended that primary cells should not be cultured past passage five 
due to cell aging, resulting in loss of phenotype. Fig 4.1.1 and 4.1.2 show images taken of 
endothelial cells and human vascular smooth muscle cells at passage 4. In the images, the 
endothelial cells are at approximately 50% confluency and the human vascular smooth 
muscle cells are at approximately 80-90% confluency.  
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Figure 4.1.1. Human endothelial cells, passage 4, approximately 50% confluency 
 
 
 
 
Figure 4.1.2. Human vascular smooth muscle cells, passage 4, 80-90% confluency 
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4.2 RT-PCR 
RNA was collected from primary cells to be used for RT-PCR. Tables 4.2.1 and 4.2.2 
show the RNA concentration from each primary cell line, and the amount used to give a 
total of 1µg of RNA in each sample for reverse transcription. All samples were made up 
to a final volume of 10µls. HAOSMC samples had an average RNA concentration of 
0.218µg/µl. The average RNA concentration was 0.2325 µg/µl in passage 4, and 0.2033 
µg/µl in passage 5. On average, the RNA concentration was 12.6% lower in passage 5 
compared to passage 4. HAOEC RNA concentrations were over 50% lower than 
HAOSMCs, with the average being 0.083µg/µl. The average RNA concentration in 
passage 5 was 28.33% higher than the average RNA concentration in passage 6 (0.0967 
µg/µl in passage 5 and 0.0693 µg/µl in passage 6). There was a larger drop in RNA 
expression between passages in HAOECs, than in HAOSMCs (28.33% vs. 12.6%).  
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Samples Conc. µg/µl RNA (µl) H2O (µl) Total 
Vol.(µls) 
SMC passage 4 
Control 1 
0.28 3.57 6.43 10 
SMC passage 4 
Control 2 
0.27 3.7 6.3 10 
SMC passage 4 
Control 3 
0.22 4.46 5.54 10 
GM-CSF 10ng/ml 1 0.21 4.81 5.19 10 
GM-CSF 10ng/ml 2 0.25 4.03 5.97 10 
GM-CSF 10ng/ml 3 0.22 4.46 5.54 10 
GM-CSF 50ng/ml 
1+ IL4 100ng/ml 
0.20 5 5 10 
GM-CSF 50ng/ml 
2+ IL4 100ng/ml 
0.25 4.03 5.97 10 
GM-CSF 50ng/ml 
3+ IL4 100ng/ml 
0.26 3.91 6.09 10 
GM-CSF 50ng/ml 1 0.26 3.91 6.09 10 
GM-CSF 50ng/ml 2 0.19 5.21 4.79 10 
GM-CSF 50ng/ml 3 0.18 5.43 4.57 10 
SMC passage 5 
control 1 
0.2 5 5 10 
SMC passage 5 
control 2 
0.184 5.43 4.57 10 
SMC passage 5 
control 3 
0.192 5.21 4.79 10 
GM-CSF 10ng/ml 1 0.192 5.21 4.79 10 
GM-CSF 10ng/ml 2 0.216 4.63 5.37 10 
GM-CSF 10ng/ml 3 0.192 5.21 4.79 10 
GM-CSF 50ng/ml 
1+IL4 100ng/ml 
0.168 5.95 4.05 10 
GM-CSF 50ng/ml 
2+IL4 100ng/ml 
0.248 4.03 5.97 10 
GM-CSF 50ng/ml 
3+IL4 100ng/ml 
0.216 4.63 5.37 10 
GM-CSF 50ng/ml 1 0.2 5.00 5 10 
GM-CSF 50ng/ml 2 0.224 4.46 5.54 10 
GM-CSF 50ng/ml 3 0.208 4.81 5.19 10 
Table 4.2.1 Dilutions of HAOSMCs RNA to prepare first 24 samples for RT-PCR 
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Samples Conc. µg/µl RNA (µl) H2O 
(µl) 
Total Vol. 
(µls) 
EC P5 Control 1 0.136 3.7 6.3 10 
EC P 5 Control 2 0.104 4.8 5.2 10 
EC P5 Control 3 0.096 5.2 4.8 10 
GM-CSF 10ng/ml 1 0.072 6.9 3.1 10 
GM-CSF 10ng/ml 2 0.088 5.7 4.3 10 
GM-CSF 10ng/ml 3 0.096 5.2 4.8 10 
GM-CSF 50ng/ml 
1+ IL4 100ng/ml 
0.104 4.8 5.2 10 
GM-CSF 50ng/ml 
2+ IL4 100ng/ml 
0.08 6.3 3.8 10 
GM-CSF 50ng/ml 
3+ IL4 100ng/ml 
0.088 5.7 4.3 10 
GM-CSF 50ng/ml 1 0.104 4.8 5.2 10 
GM-CSF 50ng/ml 2 0.096 5.2 4.8 10 
GM-CSF 50ng/ml 3 0.096 5.2 4.8 10 
     
EC P6 Control 1 0.08 6.3 3.8 10 
EC P6 Control 2 0.072 6.9 3.1 10 
EC P6 Control 3 0.072 6.9 3.1 10 
GM-CSF 10ng/ml 1 0.064 7.8 2.2 10 
GM-CSF 10ng/ml 2 0.08 6.3 3.8 10 
GM-CSF 10ng/ml 3 0.072 6.9 3.1 10 
GM-CSF 50ng/ml 
1+ IL4 100ng/ml 
0.072 6.6 3.1 10 
GM-CSF 50ng/ml 
2+ IL4 100ng/ml 
0.08 6.3 3.8 10 
GM-CSF 50ng/ml 
3+ IL4 100ng/ml 
0.056 8.9 1.1 10 
GM-CSF 50ng/ml 1 0.064 7.8 2.2 10 
GM-CSF 50ng/ml 2 0.064 7.8 2.2 10 
GM-CSF 50ng/ml 3 0.056 8.9 1.1 10 
Table 4.2.2 Dilutions of HAOECs RNA to prepare second 24 samples for RT-PCR 
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4.3. Plasmid standard curve results 
In order to accurately detect sGC transcript numbers, a standard curve with 
known transcript numbers needed to be set up before our primary cell RNA samples 
could be QPCR analysed. To set up these standard curves previously PCR-amplified α1 
and β1 were ligated separately into the plasmid vector pCR-Blunt and transformed into 
competent cells. Plasmid DNA was extracted, measured on a spectrophotometer and 
electrophoresed on a 2% agarose gel. Plasmid standards underwent restriction digest to 
ensure α1 and β1 sGC had been successfully ligated to pCR-Blunt. 
 
4.3.1 Spectrophotometer results 
 Plasmid DNA was extracted and the DNA concentration was measured on a 
spectrophotometer (Table 4.3.1.1) 
 
Plasmid µl added 
Concentration 
(µg/µl) Abs Average Conc.  
pCR-Blunt- α1 sGC 2 0.075 0.003 0.0781 
 4 0.0875 0.007  
 6 0.0833 0.01  
 8 0.075 0.012  
 10 0.07 0.014  
     
pCR-Blunt- β1 sGC 2 0.05 0.002 0.0536 
 4 0.05 0.004  
 6 0.05 0.006  
 8 0.0625 0.1  
 10 0.055 0.011  
 12 0.05416 0.013  
 
Table 4.3.1.1 α1 and β1 plasmid absorbance and concentration to prepare standard curve. 
An increase in volume gave a corresponding increase in concentration and absorbance. 
  
The absorbance was multiplied by a factor of 50 and the dilution factor to calculate the 
concentration of the DNA in µg/ml. Dividing by 1000 gave the concentration in µg/µl. 
These results were then plotted against the volume and the equation of the line 
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determined (Fig 4.3.1.1 and 4.3.1.2). The concentration of each plasmid in 1µl was 
calculated. 
 
Alpha Std Curve y = 0.0675x + 0.055
R2 = 0.9746
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Figure 4.3.1.1 Graph showing α1 sGC-pCR Blunt concentration (µg/µl) plotted against 
the volume (microlitres) 
 
Beta Std Curve y = 0.0571x - 0.0167
R2 = 0.9796
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Figure 4.3.1.2 Graph showing β1 sGC-pCR Blunt concentration (µg/µl) plotted against 
the volume (microlitres) 
100 
 
4.3.2 Plasmid standard electrophoresis and restriction digest 
α1 and β1 sGC were successfully ligated and transformed into competent cells. 
The plasmid DNA was extracted and an aliquot run on a 2% agarose gel to evaluate the 
concentration extracted (Fig 4.3.2.1). CHECK NUMBERING OF FIGURES. 
 
 
Figure 4.3.2.1 2% agarose gel of DNA extracted from α1 and β1 pCR-Blunt 
transformation. Lanes 1-5 contain α1 sGC plasmid DNA, and lanes 6-10 contain β1 sGC 
plasmid DNA.  
 
Plasmids were restricted with EcoR1 to confirm the presence of α1 and β1 sGC inserts. 
The restriction digest on our plasmid standards was successful. EcoR1 cut on either side 
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of the α1 sGC and β1 sGC fragment. β1 (2.2kb) being smaller in size than α1 (2.6kb), ran 
slightly further on the gel (Fig. 4.3.2.2).  
 
 
 
 
Figure 4.3.2.2- 2% agarose gel of pCR-Blunt-alpha sGC/pCR-Blunt-beta sGC restricted 
with EcoR1. 
 
 
4.3.3 QPCR of standard curves 
We needed a way of determining the number of α1 and β1 sGC transcripts. In 
order to achieve this, we set up a standard curve for α1 and β1 using pCR-Blunt. This set-
up was successful. Figures 4.3.3.1 and 4.3.3.2 show the standard curve plots for our α1 
and β1 standard curves. The Ct (threshold cycle) value on the y-axis is the number of PCR 
cycles that elapse before the threshold is reached and is a measure of the input DNA. The 
higher the Ct value, the smaller the initial amount of DNA in the sample. The x-axis 
shows the log of the dilution. The dilutions of each standard were very accurate, 
producing a straight line through the points. The R
2
 value of the α1 sGC standard curve 
was 0.996 and the R
2
 value for the β1 sGC standard curve was 0.999. A random sample 
was run with the standard curves to see where it would fall on the curve and to give an 
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idea of any dilutions which might be needed. Using the curve, it would be possible to 
determine the number of transcripts in our primary cell samples 
 
Tables 4.3.3.1 and 4.3.3.2 show the α1 and β1 Ct values for each standard and the 
corresponding number of DNA molecules present. Each sample was performed in 
triplicate, with a high level of accuracy being seen between each one.  
 
 
 
 
Figure 4.3.3.1- α1 sGC-pCR Blunt standard curve. Y-axis shows the Ct value which is the 
number of PCR cycles elapsed and is a measure of the input DNA. The x-axis values are 
the log of the dilutions of each standard. The blue squares depict the individual standards 
and the small x’s are the results of a single random sample which underwent a serial 
dilution to see where it would fall on the curve.  
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Standard Curve 
 α1 sGC 
Quantity 
(transcript 
number) Ct 
300000 17.414785 
300000 17.558645 
300000 17.530777 
30000 20.971413 
30000 21.47954 
30000 21.611876 
3000 25.135029 
3000 24.59122 
3000 25.204159 
300 29.035532 
300 28.900871 
300 29.175179 
30 32.839314 
30 31.853695 
30 32.234535 
 
Table 4.3.3.1 Ct values for each dilution of the α1 sGC standard curve. Quantity depicts 
the transcript numbers of α1 sGC in each sample. Each sample was performed in 
triplicate. The higher the Ct value, the smaller the initial amount of DNA in the sample.  
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Figure 4.3.3.2- β1 sGC-pCR-Blunt plasmid standard curve. Y-axis shows the Ct value 
which is the number of PCR cycles elapsed and is a measure of the input DNA. The x-
axis values are the log of the dilutions of each standard. The blue squares depict the 
individual standards and the small x’s are the results of a single random sample which 
underwent a serial dilution to see where it would fall on the curve. 
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Standard Curve 
 β1 sGC 
 Quantity 
(transcript 
number) Ct 
300000 19.730127 
300000 19.955639 
300000 19.790623 
30000 23.564941 
30000 23.699537 
30000 23.71591 
3000 27.326616 
3000 27.388403 
3000 27.388237 
300 31.324411 
300 31.692593 
300 31.233912 
30 35.541477 
30 35.317497 
30 35.276806 
  
 
Table 4.3.3.2 Ct values for each dilution of the β1 sGC standard curve. Quantity depicts 
the transcript numbers of β1 sGC in each sample. Each sample was performed in 
triplicate. The higher the Ct value, the smaller the initial amount of DNA in the sample. 
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Figures 4.3.3.3 and 4.3.3.4 show the amplification plots for GAPDH (loading control) 
and β1 sGC. Plots show ΔRn vs. cycle number. Rn represents the raw fluorescence signal 
over time. ΔRn values are corrected for the background signal which gives the correct 
fluorescence increase. The detection method is based on the changes in fluorescence, 
which are proportional to the increase of the target. Fluorescence is monitored during 
each PCR cycle, providing an amplification plot, allowing the reaction to be followed in 
real time. 
 
 
 
Figure. 4.3.3.3. Amplification plot of serial diluted GAPDH cDNA (loading control). 
ΔRn vs. cycle number. The detection method is based on the changes in fluorescence. 
The green line represents the threshold above background fluorescence. ΔRn represents 
the increase in fluorescence above the threshold which is monitored during each PCR 
cycle, providing an amplification plot.  
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Figure 4.3.3.4. Amplification plot of serial diluted β1 sGC cDNA to prepare a standard 
curve. ΔRn vs. cycle number. The detection method is based on the changes in 
fluorescence. The green line represents the threshold above background fluorescence. 
ΔRn represents the increase in fluorescence above the threshold which is monitored 
during each PCR cycle, providing an amplification plot.  
 
The setting up of our two standard curves was complete. α1 and β1 sGC had been 
successfully ligated to pCR-Blunt, the DNA isolated and restricted to ensure this was the 
case and the concentration determined. QPCR was then performed using our standards 
which were serially diluted. Our standard curve plots yielded straight lines which showed 
a high level of accuracy. Now that we had made working tested standards, we could go 
ahead with the QPCR of the mRNA previously isolated from our HAOSMCs and 
HAOECs to determine the effect cytokine treatment had on the expression of sGC.  
Formatted: Centered
110 
 
4.4. QPCR on human vascular smooth muscle cells 
We wanted to know the effects GM-CSF and IL-4 would have on mRNA levels 
of sGC. In order to examine this, QPCR was carried out on human vascular smooth 
muscle cells to determine if mRNA levels of α1 and β1 sGC were affected. All results 
were normalised against GAPDH to ensure equal loading of samples.  
Treatment of HAOSMCs with GM-CSF and IL-4 resulted in an increase of α1 and 
β1 sGC levels. Figure 4.4.1 shows results obtained for α1 sGC on HAOSMCs at passage 
4. Cells showed a significant increase in the transcript number of α1 sGC in cells treated 
with a combination of GM-CSF at 10ng/ml and IL-4 at 100ng/ml (p value=0.037). This 
combination of cytokines resulted in an increase in the level of α1 sGC from a transcript 
number of approximately 75 for our control unstimulated cells to over 100 (Fig 4.4.1). 
Treatment using GM-CSF at 50ng/ml approached significance with a transcript number 
of approximately 85 (p value=0.059). A lower dose of GM-CSF of 10ng/ml gave no 
significant result compared to control, and even caused a slight but negligible drop in 
transcript number.  
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Figure 4.4.1 QPCR results of α1sGC on Human Primary Vascular Smooth Muscle Cells 
at passage 4. Each QPCR graph depicts the transcript number normalised using our 
loading control GAPDH on the x-axis, and the treatment received by each sample on the 
y-axis. n=3 in all groups. *=significantly greater than control 
 
 
In order to examine the effect of continued passaging of the cells, HAOSMCs 
were cultured to passage 5. Figure 4.4.2 shows the results for α1 sGC obtained at passage 
5. At passage five there was a small increase in the overall transcript number of α1 sGC 
when compared to passage 4. This could be due to the smooth muscle cells growing 
better at passage 5 than at passage 4. There is a significant increase in α1 sGC levels 
compared to the control (p value=0.023) when GM-CSF and IL-4 were used in 
combination (Fig 4.4.2). When the cytokines were used in combination, the transcript 
number doubled compared to the control cells. GM-CSF at 10ng/ml and at 50ng/ml did 
not affect the transcript number in any significant way.  
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Figure 4.4.2 QPCR results of  α1 sGC on Human Primary Vascular Smooth Muscle Cells 
at passage 5. n=3 in all groups *=significantly greater than control. 
 
 
β1 sGC was examined under the same conditions. Figures 4.4.3 and 4.4.4 show 
results obtained for β1 sGC in HAOSMCs at passage 4 and passage 5 respectively. The 
transcript number of α1 was approximately 75, compared with nearly 10,000 transcripts 
of β1. There was a large increase in transcript number when the cells were treated with 
GM-CSF and IL-4 in combination. Levels nearly doubled compared to control cells after 
cytokine treatment. Unfortunately, one of the samples treated with the combination of 
cytokines was lost during QPCR anaylsis. As a result statistical analysis could not be 
performed to determine if there was any significance for this sample. GM-CSF on its own 
at both the lower and higher doses had no significant effect. 50ng/ml resulted in a 
decrease of β1 sGC, but this decrease was only by a transcript number of approximately 
2500. The transcript number of β1 sGC for the control cells at passage 4 was over 130X 
greater than the α1 sGC control cells. (Fig. 4.4.3). 
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Figure 4.4.3 QPCR results of  β1 sGC on Human Primary Vascular Smooth Muscle Cells 
at passage 4.  n=3 in all groups except combined cytokine group 
 
There was very little difference in transcript numbers of β1 sGC levels between 
passage 4 and passage 5. Cytokine treatment did not cause a significant change in 
transcript numbers (p value=0.249), however higher levels were achieved when GM-CSF 
and IL-4 were used in combination (Fig 4.4.4). GM-CSF used on its own at both 
concentrations decreased β1 sGC levels slightly, but this decrease was not significant. As 
was observed with passage 4, there was a very large difference in the levels of β1 sGC 
compared with α1 sGC. β1 sGC levels were almost one hundred times greater than that 
seen with α1 sGC.  
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Figure 4.4.4 QPCR results of  β1 sGC on Human Primary Vascular Smooth Muscle Cells 
at passage 5. No significance between groups 
 
 
4.5. QPCR data on endothelial cells 
QPCR was carried out on HAOECs at passage 5 and passage 6. Endothelial cells 
were grown to passage 6 as they grew slower than smooth muscle cells. Opposite effects 
were seen in endothelial cells compared with smooth muscle cells, with transcript levels 
decreasing as a result of cytokine treatment.  
Figure 4.5.1 shows α1 sGC levels at passage 5 in ECs. The levels of α1 sGC in 
ECs cells at passage 5 were almost 15 times higher than that seen in smooth muscle cells. 
Cytokine treatment resulted in a decrease in transcript levels, with the combination of 
cytokines achieving the greatest decrease (Fig. 4.5.1). This decrease was significantly 
different (p value=0.037) from control values. α1 sGC levels following treatment with 
GM-CSF at 50ng/ml were lower but not significant from control levels (p value=0.056). 
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Treatment with 10ng/ml GM-CSF led to lower levels of α1 sGC when compared to 
control, but this was again not significant (p value=0.248).  
 
 
Figure 4.5.1 QPCR results of α1 sGC on Human Primary Endothelial Cells at passage 5. 
Treatment with the combination of cytokines produced a significant decrease in transcript 
numbers. n=3 in all groups. *=significantly lower than control. 
 
 
Figure 4.5.2 shows α1 sGC levels at passage 6. There was a large decrease in α1 transcript 
numbers between passage 5 and passage 6. Levels dropped by approximately 50% and 
this was probably due to cell aging and a lower expression of sGC. Levels of α1 sGC in 
cells treated with GM-CSF and IL-4 did not drop as much as the control cells and cells 
treated with 10ng/ml and 50ng/ml GM-CSF.  Treatment with GM-CSF at 10ng/ml 
resulted in a slight increase in transcript numbers which was close to significant (p 
value=0.05519). In addition to this, treatment with 50ng/ml GM-CSF caused a reduction 
in transcript level which approached significance (p value=0.055). However, overall there 
was no significant difference between treated groups and control.  
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Figure 4.5.2 QPCR results of  α1 sGC on Human Primary Endothelial Cells at passage 6. 
n = 3 in all groups. No significant difference between groups.  
 
 
Figures 4.5.3 and 4.5.4 show results obtained for β1 sGC. There was a significant 
decrease in transcript numbers of β1 sGC when cytokines were used in combination (p 
value=0.001138). This decrease reflected the same trend seen for α1 sGC. GM-CSF at 
50ng/ml showed a slight decrease in transcript number. As with smooth muscle cells, β1 
levels were much higher than α1 levels, with the control levels of β1 sGC at passage 5 
nearly seven times higher than α1 sGC.  
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Fig 4.5.3. QPCR results of β1 sGC on Human Primary Endothelial Cells at passage 5. 
Treatment with the combination of cytokines yielded a significant decrease in transcript 
number. n=3. *=significantly lower than control.  
 
 
At passage 6, there was no significant drop in the levels of β1 sGC at passage 6, 
however GM-CSF cells treated with 50ng/ml approached significance (p value=0.0531). 
As with α1 sGC, the transcript number of the control cells was lower in passage 6 
compared with passage 5. However levels of β1 sGC treated with GM-CSF and IL-4 did 
not drop as much as the other groups. β1 sGC levels at passage 6 were around 4 times 
higher than α1 levels at passage 6. 
 
118 
 
 
Fig 4.5.4. QPCR results of β1 sGC on Human Primary Endothelial Cells at passage 6. No 
significant difference between groups.  
 
 
QPCR results on HAOSMCs for α1 sGC showed that the combination of 
cytokines resulted in a significant increase in transcript numbers compared with the 
control among both passages. For β1 sGC, in passage 4 the combination of cytokines 
resulted in a significant increase in transcript numbers compared with the control. In 
passage 5 cytokine combination causes an increase in transcript number but this increase 
was not significant.  
 
HAOEC results showed that α1 sGC levels in passage 5 decreased significantly compared 
with the control. β1 sGC levels also had significant decreases when treated with the 
combination of cytokines. For both α1 and β1, no significant decreases were seen in 
passage 6.  
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At this stage in the project we had cultured our primary cells, cytokine-treated them, 
isolated RNA and protein, set up a QPCR standard curve and ran QPCR on all 48 of our 
primary cell RNA samples. Having achieved the results we had using our isolated 
mRNA, the next step was to look at the protein levels of sGC. We wanted to see if the 
protein levels reflected mRNA levels in our samples.  
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4.6 Antibody experiments to detect α1 and β1 sGC in BE2 and Sf9 cell lysates 
Now that our mRNA had been QPCR analysed, the next stage of the study looked 
at protein levels. In order to do this we had to optimise a selection of antibodies for use 
on our primary cell protein samples. The laboratory had several anti-α1 and β1 sGC 
antibodies available for use, but at no stage had any tests been carried out to determine 
how specific these antibodies were, or if they worked at all. Our protein samples were 
precious and not to be wasted, therefore, BE2 and Sf9 cells expressing recombinant sGC 
were used to carry out this evaluation. In addition to determining the ideal antibody for α1 
and β1 sGC detection, the antibody dilution and exposure time also had to be optimised. 
For most of the antibodies, the dilutions used were 1:1000 or 1:2000, with higher 
dilutions being used for some (tables 4.6.1.1 and 4.6.2.1). Exposure times also varied 
from a few seconds to overnight depending on the strength of the signal of the membrane. 
Exposure was initially for one minute, and was increased or decreased depending on the 
signal strength.  The success of the antibody evaluation on BE2 and Sf9 cell lysates 
varied. 
 
 
4.6.1 Antibody experiments to detect α1 sGC in BE2 and Sf9 cell lysates 
α1 sGC is approximately 81kDa. Therefore, in order for an antibody to detect 
correct α1 there must be a distinct and clear band in the 81kDa region. Figure 4.6.1.1 
shows the results of anti α1 F9908-1 on BE2 lysates at increasing protein concentrations. 
A dilution factor of 1:1000 was used as this was a standard dilution for anti-α1 sGC 
antibodies. The antibody looks specific for a large band running lower than the 81kDa 
molecular weight marker. The higher the BE2 lysate concentration, the higher the signal. 
This large band runs too low on the gel to be α1 sGC. This α1 antibody is not specific for 
α1. The specificity it shows may due to an immune response to something else in the 
sample. This antibody was subsequently not used on our primary cell samples. 
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Figure. 4.6.1.1. Western blot carried on BE2 lysate (2.5µg/µl) using anti-α1 F9908-1 
(serum) at a dilution of 1:1000. The secondary antibody was anti-rabbit.  
 
The bands recognized by anti α1 sGC 9908-2 (Fig. 4.6.1.2) ran too low to be real α1. The 
antibody did appear to be specific for one band in particular, and increased in intensity 
with increasing protein concentration, however this band was not α1 sGC due to its size 
being too small. This antibody was therefore not used any further experiments.  
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Figure. 4.6.1.2. Western blot carried out on BE2 lysates (5, 37.5µg) at different protein 
concentrations, and Sf9 cell lysates (α1/α1 and β1/β1). Anti-α1 sGC 9908-2 (serum) at a 
dilution of 1:1000 was used.  
 
 
 
Another anti-α1 sGC antibody used was 1168-2 (Fig. 4.6.1.3). This antibody was specific 
for the N-terminal of α1 sGC. It reacted with several bands in the BE2 cells lysate, 
including a small band that ran slightly lower than real α1 sGC. It did not recognize any 
protein from the Sf9 cell lysates, including recombinant α1. As a result of this, it could 
not be said that this antibody was specific for α1 and it subsequently wasn’t used.  
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Figure. 4.6.1.3. Anti-α1 1168-2 (N-terminal), dilution 1:2000, used on BE2 (5µg, 35µg) 
and Sf9 cell lysates (β1/β1, α1/α1).  
 
A successful antibody used was anti-α1 sGC 5214’ (Fig 4.6.1.4). This antibody 
recognized a clean, sharp band close to the 80kDa, which looked specific for true α1 sGC. 
The band increased in intensity with increasing protein concentration. The antibody also 
reacted strongly with a band at approximately 160kDa which increased with protein 
concentration. As mentioned before, this may be the sGC α1β1 dimer which remains 
undissociated in the denatured protein sample. This dilution for this antibody was very 
low, however we did go on to use this α1 antibody on our primary cell samples. 
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Figure. 4.6.1.4. Western blot carried out using BE2 cells lysates at: 5, 7.5, 25 and 50µg. 
Anti-α1 sGC 5214’ at a dilution of 1:100 was used.  
 
 
Anti-α1 9908 (C-α new) was an antibody which showed specificity for α1 sGC 
(Fig 4.6.1.5). It recognized a clean, sharp band at approximately 80kDa which is the 
correct running position for true α1. The dilution of this antibody was very low as it had 
been company purified. It also showed specificity for a double band between the 216 and 
146 molecular weight markers. This may be the α1β1 dimer of sGC, however work is on-
going in the laboratory to determine if some of the sGC dimer run on a western blot 
remains undissociated after denaturation (unpublished data).  
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Figure. 4.6.1.5. Western blot carried out using BE2 cell lysates at 5, 7.5, 25 and 50µg. 
Anti-α1 9908 (C-α new) used at a dilution of 1:10.  
 
A total of ten α1 sGC antibodies were evaluated (Table 4.6.1.1). Dilutions ranged 
from 1:10 to 1:2000, with four detecting the correct band. The antibody 5214’ which was 
re-boosted 4096 at a dilution of 1:100 performed the best and it was decided this antibody 
would be used on our isolated protein. It was surprising that only about one third of the 
antibodies evaluated recognised the α1 band. These antibodies were being used regularly, 
and in some cases, being bought from companies, so they were expected to perform 
better than they did.  
 
 
126 
 
 
 
Panel of anti α1 sGC Antibodies used 
 
 Antibody Epitope Dilution Correct band identified 
     
1 9908-1 (First Boost) C-Terminal 1:1000 No 
2 9908-2 (Second Boost) C-Terminal 1:1000 No 
3 9908-0 (Trial Sample) C-Terminal 1:1000 No 
4 9907-1 (First Boost) C-Terminal 1:1000 No 
5 9908 (C-α new) C-Terminal 1:10 Yes 
6 1168-2 (Second Boost) C-Terminal 1:2000 No 
7 F1168 (company purified) C-Terminal  1:10 No 
8 1168-1 N-Terminal 1:2000 No 
9 4096 C-Terminal 1:1000 Yes 
10 4096 C-Terminal 1:500 Yes 
11 4096 C-Terminal 1:50 No 
12 5214' (4096) C-Terminal  1:100 Yes 
Table 4.6.1.1 List of α1 sGC antibodies evaluated detailing the epitope, the dilution and if 
it detected the correct protein band 
 
 
 
 
 
4.6.2. Antibody experiments to detect β1 sGC on BE2 and Sf9 cell lysates 
 
The β1 sGC subunit is approximately 79kDa. The laboratory did not have a 
selection of anti-β1 sGC antibodies as large as it did for anti α1 sGC. The anti-β1 sGC 
antibody 4843 was tested first. This recognised β1 but the band was not very strong or 
sharp. The same result was seen in the affinity purified form of the antibody. Anti-β1 sGC 
0028-2 (Fig. 4.6.2.1) recognised a band at approximately 79kDa in the BE2 lysates at 
5µg and 37.5µg. It didn’t react with anything in the α1 recombinant Sf9 lysate, but we can 
see a large dark band on the β1 Sf9 lysate sample. This dark band is due to overloading of 
the sample and the strong reactivity of the antibody for β1 sGC. A swelling on the dark 
band around the 79kDa mark can just about be seen. This corresponds to the location of 
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the β1 sGC subunit on the gel. This antibody performed well and showed good specificity. 
The company purified form of the antibody did not show any specificity. As a result of 
this, no further β1 sGC antibodies were evaluated for β1, and 0028-2 was subsequently 
used on primary cell samples. Instead, evaluations to find the optimal dilution for anti-β1 
sGC 0028-2 were performed. Table 4.6.2.1 shows the table of anti β1 sGC antibodies 
evaluated, including their dilutions and the epitope they recognise.  
                 
 
 
Figure. 4.6.2.1. Western blot carried out on Sf9 cell lysates (α1/α1, β1/β1) and BE2 cell 
lysates (5, 37.5 µg). Anti-β1 sGC 0028-2 (serum) at a dilution of 1:2000 was used.  
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Panel of anti β1 sGC Antibodies used 
 
 
Antibody 
 
Epitope 
 
Dilution 
 
Correct band identified 
 
1 4843 (affinity purified) C-Terminal 1:1000 Yes 
2 0028-2 C-Terminal  1:2000 Yes 
3 F0028 (company purified) C-Terminal  1:2000 No 
4 4843 C-Terminal 1:1000 Yes 
 
Table 4.6.2.1. List of β1 sGC antibodies evaluated detailing the epitope, the dilution and 
whether or not it detected the correct protein band 
 
A total of fourteen antibodies for both α1 and β1 sGC were evaluated: Ten α1 
antibodies and four β1, with only one of each being selected for use on primary cell 
protein samples (Table 4.6.2.2). Based on the experiments above, one α1 antibody and 
one β1 antibody were chosen. The α1 antibody selected was anti-α1 5214’ and the β1 
antibody selected was anti- β1 0028-2. Both of these antibodies showed a strong signal 
for bands at the appropriate molecular weight and their signal increased with higher 
protein concentrations of BE2 and Sf9 cell lysates. As a result of this evaluation, 
companies which provided some of the antibodies were contacted and were no longer 
considered when purchasing new antibodies. 
 
 
 
Antibody Dilution 
Alpha 5214' C-Terminal  1:160 
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 1:250 
Beta 0028 C-Terminal 1:1500 
 1:1000 
Beta Actin 1:5000 
 1:10000 
 
Table 4.6.2.2 Final antibodies chosen and concentrations used on primary cell samples 
 
 
 
 
4.7. Bradford assays 
After the antibody evaluations had been performed, Bradford assays were carried out on 
all samples to determine their protein concentration. This was done in order to ensure 
equal loading of samples in each lane. The final volume of samples in each well was 
100µl.  
 
Figure 4.7.1 shows an example of one of the results of the Bradford Assays performed on 
HAOECs at Passage 6. The absorbances read from the spectrophotometer decrease as the 
dilution increases. Lanes 1-2 are the standard curves. Lanes 3-12 show the results from 5 
of the HAOEC cell samples.  
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 Control ECP6 Sample 1 ECP6 Sample 2 ECP6 Sample 3 ECP6 Sample 4 ECP6 Sample 5 
   5µl 10µl 5µl 10µl 5µl 10µl 5µl 10µl 5µl 10µl 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.255 0.243 0.452 0.608 0.423 0.667 0.524 0.75 0.493 0.772 0.493 0.746 
B 0.358 0.388 0.36 0.441 0.373 0.451 0.375 0.489 0.38 0.504 0.38 0.457 
C 0.406 0.402 0.312 0.352 0.312 0.368 0.309 0.379 0.316 0.376 0.316 0.373 
D 0.445 0.444 0.283 0.31 0.287 0.311 0.284 0.318 0.286 0.323 0.294 0.318 
E 0.479 0.466 0.266 0.281 0.271 0.282 0.261 0.29 0.272 0.282 0.275 0.286 
F 0.507 0.507 0.263 0.267 0.273 0.275 0.263 0.271 0.265 0.272 0.265 0.275 
G 0.078 0.078 0.265 0.267 0.267 0.268 0.262 0.267 0.262 0.268 0.261 0.271 
H 0.078 0.082 0.258 0.262 0.263 0.27 0.26 0.267 0.253 0.258 0.258 0.271 
             
 
Figure 4.7.1. Absorbance values for HAOECs Passage 6. Columns 1-2 are the standard curve results. 5µl and 10µl of each sample were used. As 
the dilution increases (A-H), the absorbances decrease as less protein is present.  
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The results of the Bradford assays are shown in tables 4.7.1 - 4.7.3 below. The protein 
concentration in µg/µl was determined for all 36 samples. Each table shows the protein 
concentration and the corresponding volume added to achieve this concentration. As 
previously mentioned, there were no protein samples left from HAOSMCs at passage five, as 
samples were depleted in the initial western blot optimisation experiments.  
 
Protein determination for HAOECs and HAOSMCs 
 
 
Protein 
µg/µl 
Vol. to add per 
sample (µl) 
0.6 21 
0.36 35 
0.56 22.5 
0.53 23.77 
0.5 25.2 
0.36 35 
0.466 27 
0.366 34.4 
0.43 29.3 
0.4 31.5 
0.533 23.63 
0.5 25.2 
Table 4.7.1. HAOECs passage 5 Samples 1-12 
 
 
 
 
Protein 
µg/µl 
Vol. to add per 
sample (µl) 
0.27 35 
0.33 28.6 
0.33 28.6 
0.33 28.6 
0.36 26.25 
0.4 23.62 
0.4 23.62 
1.2 7.875 
0.37 25.5 
0.37 25.5 
1.47 6.42 
0.97 9.74 
Table 4.7.2 HAOECs passage 6 Samples 1-12 
133 
 
 
 
 
Protein 
µg/µl 
Vol. to add per 
sample (µl) 
0.4 14 
0.6 23.3 
0.566 24.7 
0.7 20 
1.2 11.66 
0.566 24.7 
0.533 26.41 
0.633 22.11 
0.6 23.33 
0.666 21 
0.733 19 
0.766 18.27 
  
Table 4.7.3 HAOSMCs passage 5 Samples 1-12 
 
Now that antibody dilutions  and protein concentrations had been determined, Western blot 
analysis began on primary cells..  
 
 
 
4.8. Western blotting results for endothelial cells. 
 
Passage 5 
Blots were carried out on endothelial cells at passage 5. All samples were carried out 
in triplicate. Each membrane was blotted with an anti α1, an anti β1 and an anti beta actin 
antibody. Some membranes were re-blotted with primary antibody at different dilutions, and 
exposed at different times depending on the result achieved in each blot. 
Figure 4.8.1 shows a blot using anti-α1 sGC 5214’ at a dilution of 1:160. In the 
antibody evaluation, a dilution of 1:100 was successful for BE2 cells, producing a strong 
band. This gave us an estimate of what dilution to use on our primary cells. Several blots 
using varying dilutions of 5214’ were carried to determine the optimum for our smooth 
muscle cells. Two distinct bands can be seen in each lane however both of these bands run 
too low to be α1 sGC. The α1 region of the membrane shows no antibody binding. There is 
also no difference in intensity between samples. The third sample of the GM-CSF at 50ng/ml 
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treated cells shows a weaker band than the others, but this is more than likely due to protein 
degradation.  
 
 
Figure 4.8.1 Western blot performed on endothelial cells at passages 5 using anti-α1 sGC 
5214’ at a dilution of 1:1500. Exposure was for 5 minutes.  
 
The membrane was washed and re-blotted with anti-β1 sGC 0028 (Fig. 4.8.2). As with 
the previous blot, more than one dilution, including the one tested on BE2 cells (1:2000) were 
used to determine which gave the strongest signal. Similar to what was seen with α1 sGC, no 
specific binding was present. There was no beta band. Some non-specific binding was 
present, but overall there was very little antibody binding to the membrane.   
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Figure 4.8.2 Western blot performed on endothelial cells at passages 5 using anti-β1 sGC 
0028 at a dilution of 1:1500. Exposure was for 2 minutes.   
 
 
Beta actin was used as a loading control to ensure approximately the same amount of 
protein was added for each sample. Figure 4.8.3 shows the binding of anti beta actin to the 
blot. Binding is strong and specific for beta actin and shows a close specificity of loading of 
each sample.  
 
 
Figure 4.8.3 Western blot performed on endothelial cells at passages 5 using anti-beta actin at 
a dilution of 1:6500. Exposure was for 5 seconds.   
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Passage 6 
The same antibodies were used on endothelial cells at passage 6 and were also 
performed in triplicate. A smaller dilution factor was used for anti-α1 sGC 5214’ than was 
used in passage 6 to try and achieve specific binding to α1 sGC (Fig 4.8.4). Like in passage 5, 
no specific α1 sGC band was present on the blot. The same two larger bands as seen in 
passage 5 were on the membrane. No specificity for α1 was seen.  
 
 
 
Figure 4.8.4. Western blot performed on endothelial cells at passages 6 using anti-α1 sGC 
5214’ at a dilution of 1:100. Exposure was for 20 minutes.   
 
The membrane was washed to ensure no anti-α1 sGC antibodies were still bound. It 
was then incubated with anti β1 sGC 0028 at a dilution of 1:1000 (Fig. 4.8.5). Other dilutions 
were used, but this one showed the strongest signal. As was seen in passage 5, no β1 antibody 
bound to the membrane. The same non-specific binding that was observed when the α1 
antibody was used can be seen again. There was no band present in the region of the 
membrane where β1 sGC should be located.  
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Figure 4.8.5 Western blot performed on endothelial cells at passages 6 using anti-β1 sGC 
0028 at a dilution of 1:1000. Exposure was for 4 minutes.   
 
 
As for passage 5, beta actin was used as a loading control. The loading for passage 6 was not 
as accurate as expected (Fig. 4.8.6). The band intensity was not as even as in passage 5. 
Bradford assays had been carried out before loading of protein samples to ensure equal 
loading. Protein denaturation is a possible reason for the differences between lanes. There 
were not enough passage 6 samples left to re-load and repeat this Western. 
 
 
Figure 4.8.6 Western blot performed on endothelial cells at passages 6 using anti-beta actin at 
a dilution of 1:6500. Exposure was for 1 minute.  
 
Despite our antibodies being evaluated before their use on our primary cells, and the 
determination of protein levels in each sample, in most blots, no α1 or β1 sGC was detected. 
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There was a lot of non-specific staining, but the correct bands were not identified. The strong 
anti beta actin antibody signal indicated that there was enough protein in the HAOEC 
samples to be detected using Western blot analysis, but it appeared from these experiments 
that sGC protein levels were expressed at a level too low to be detected in routine Western 
blotting.  
 
 
Results of combined P5 and P6 samples. 
 
As there was little or no antibody binding to protein cell samples, we combined the 
triplicate samples together in an attempt to load the highest amount of protein into each well. 
Figure 4.8.7 shows the results of a Western blot using combined passage 5 and passage 6 
endothelial cells. Anti-α1 sGC 5214’ at a dilution of 1:160 was used. As can be seen in the 
blot, there is a faint band at approximately 80kDa which could be α1 sGC, however even if it 
is α1, the band is too faint to see any change in protein levels between samples.  
 
 
Figure 4.8.7 Western blot performed on endothelial cells at passages 5 and 6 using anti-α1 
5214’ at a dilution of 1:160. Exposure was for 15 minutes. Ctrl=Control cells, 10ng/ml=GM-
CSF at 10ng/ml, GM/IL=GM-CSF at 10ng/ml+IL4 and 10ng/ml, 50ng/ml=GM-CSF at 
50ng/ml.  
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In figure 4.8.8 anti-β1 sGC was used on the combined samples. BE2 was used as a 
control. No β1 sGC band can be seen on the blot. There is a faint band at approximately 
80kDa but this appears to be the band picked up by anti-α1 sGC.  
 
 
 
Figure. 4.8.8 Western blot performed on endothelial cells at passages 5 and 6 using anti-β1 
0028 at a dilution of 1:1000. Exposure was for 12 minutes. Ctrl=Control cells, 10ng/ml=GM-
CSF at 10ng/ml, GM/IL=GM-CSF at 10ng/ml+IL4 and 10ng/ml, 50ng/ml=GM-CSF at 
50ng/ml. 
 
 
The purpose of performing Western blots on our primary cell protein samples was to 
see if protein levels of HAOEC α1 and β1 sGC were affected in the same way as mRNA 
levels. We found that protein levels of sGC subunits are too low, even when samples are 
combined, to be detected by our antibodies. Non-specific binding was seen in some blots, but 
no bands were detected that were the correct size. We know from the beta actin that there 
were high levels of protein in the samples but sGC protein levels were not as high. The next 
step was to see if we got the same results using the protein samples from our HAOSMCs. 
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4.9. Western blotting results  for smooth muscle cells 
During the  initial western blotting optimisation experiments, passage 4 smooth 
muscle cell protein samples were used up. This meant that Western blots were carried out on 
smooth muscle cells at passage 5. All samples were run in triplicate. In figure 4.9.1, there are 
three rows of bands around 80kDa. The top band is α1 sGC, and the next lower one is most 
likely β1 sGC. The antibody appears to be picking up both subunits.  
 
 
 
Figure 4.9.1 Western blot performed on smooth muscle cells at passages 5 using anti-α1 sGC 
5214’ at a dilution of 1:160. Exposure was for 5 minutes.  
  
Figure 4.9.2 shows a blot performed using anti-β1 sGC. In this blot, the control 
samples and the sample treated with GM-CSF at 10ng/ml did not show bands in the β1 sGC 
region. However, protein samples treated with GM-CSF at 50ng/ml showed distinct dark 
bands in the β1 region. Protein samples from cells treated with GM-CSF and IL-4 showed 
dark bands which appeared to be β1 sGC. One of these bands was not as strong as the other 
but this was more than likely due to protein degradation. 
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Figure 4.9.2 Western blot performed on smooth muscle cells at passages 5 using anti-β1 sGC 
0028 at a dilution of 1:1500. Exposure was for 1 minute.   
 
 
Once again beta actin was used as a loading control. Loading between samples was fairly 
even. The anti beta actin antibody reacted very strongly (Fig. 4.9.3). 
 
 
 
Figure 4.9.3 Western blot performed on smooth muscle cells at passages 5 using anti beta 
actin at a dilution of 1:5000. Exposure was for 5 seconds. 
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Results of combined P5 and P6 samples. 
 
As with the endothelial cells, smooth muscle cell protein samples performed in 
triplicate were also combined to maximise the amount of protein in each band. Anti-α1 sGC 
at a dilution of 1:160 was incubated for 15 minutes. As can be seen in figure 4.9.4, α1 sGC is 
present in the control BE2 cells, but no α1 sGC is present in our combined smooth muscle cell 
samples. This blot indicates that either none, or very low levels of α1 sGC are present in 
primary smooth muscle cells.  
 
 
Figure 4.9.4 Western blot performed on smooth muscle cells at passages 5 using anti-α1 sGC 
at a dilution of 1:160. Exposure was for 15 minutes.  
 
 
Anti-β1 sGC did not show any clear binding or specificity for β1 sGC on the blot. Some faint 
non-specific binding was present but this was not β1 (Fig. 4.9.5).   
 
 
Figure 4.9.5 Western blot performed on smooth muscle cells at passages 5 using anti-β1 sGC 
at a dilution of 1:1000. Exposure was for 12 minutes.  
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Anti beta actin showed specificity for beta actin, and gave four clear, sharp bands (Fig 
4.9.68). Once again, it was used as a control to ensure our antibodies were showing 
specificity.  
 
Figure 4.9.69 Western blot performed on smooth muscle cells at passages 5 using anti beta 
actin at a dilution of 1:10000.  
 
 
The antibody evaluation had been performed and was successful, and the best α1 and 
β1 antibodies were selected to be used on the primary cell protein samples. It was not known 
before this study if primary cells were suitable to be used for the detection of sGC using 
Western blot analysis. These results show that HAOECS and HAOSMCs do not express 
either subunit of sGC at high enough levels to be detected by the chosen antibodies.  
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4.10. Splice variant work 
 
Alternative pre-mRNA splicing is a central mode of genetic regulation in higher 
eukaryotes. Variability in splicing patterns is a major source of protein diversity from the 
genome (Black DL, 2003). It is one of the most important mechanisms to generate protein 
isoforms and changes the structure of transcripts and their encoded proteins. Alternative 
splicing determines the binding properties, intracellular localisation, enzymatic activity, 
protein stability and post-translational modifications of a large number of proteins. Evidence 
is now accumulating that alternative splicing coordinates physiologically meaningful changes 
in protein isoform expression and is a key mechanism to generate the complex proteome of 
multicellular organisms (Stamma S et al., 2005). 
A307838 is a β1 sGC splice-form. Its function and significance is not known and in 
this study, we set about cloning it into a plasmid vector for future viral vector expression and 
enzymatic studies. We did this by separating it into 2 separate fragments: fragment 1 and 
fragment 2 (figure 4.10.1). Fragment 2 had previously been ligated to pBacPak8 (pBacPak8-
fragment2) so work was mostly with fragment 1 and its incorporation into pCR-Blunt and 
then pBacpak8.  
Refer to the figure 4.10.1 on next page. 
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Figure 4.10.1 Insert a legend hereDiagram showing the cloning procedure of A307838. 
cDNA was PCR amplified using specific primers to amplify it separately as 2 fragments (1 
and 2). These were then ligated and amplified separately into two different vectors to be 
joined again in the plasmid vector pBacPak8. 
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4.10.1 Amplification of fragment 1 
 
The results of a PCR to amplify fragment 1 are shown in figure 4.10.1.12. Fragment 1 
was successfully amplified as can be seen from the sharp band between the 1.5kb and 2.0kb 
markers. This PCR product was then ligated to pCR-Blunt and transformed in competent 
cells.  
 
 
Figure 4.10.1.12. 2% agarose gel of PCR product showing isolated fragment 1. 
 
 
4.10.2. DNA Extraction using Miniprep 
 
Plasmid DNA was extracted from our competent cells then underwent restriction 
digests to determine if they had successfully taken up our plasmid. The standard DNA 
extraction kit used in the laboratory was the Qiagen QIAprep Spin Miniprep Kit. However 
during the course of many minipreps, DNA yields began to get lower and lower. The quality 
of the kit came under question and two other DNA extraction kits were evaluated to see how 
they would compare.  
The first kit tested was the NucleoSpin Plasmid kit. Figures 4.10.2.13 and Fig 
4.10.2.24 show the results of this evaluation. The Qiagen kit was used on samples in lanes 1-
10, and the NucleoSpin kit was used on samples in lanes 11-20. There was no DNA observed 
in the lanes where the NucleoSpin kit was used. The DNA yield from the Qiagen kit while 
not very high, still performed better than the NucleoSpin kit.  
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148 
 
 
 
 
Figure 4.10.2.13. Gel showing DNA extraction from samples 1-12. 1-10 were extracted using 
the Qiagen kit. 11-12 were extracted using the new NucleoSpin Plasmid kit.  
 
 
 
 
 
 
Figure 4.10.2.24. Gel of DNA from samples 13-20 using NucleoSpin Plasmid Kit. 
 
 
The second kit evaluated was the Promega PureYield
TM
 Plasmid Miniprep System. 
The results can be seen in figure 4.10.2.35. Samples 1-5 had practically no DNA present, 
showing that the Qiagen kit was no longer working. The Promega kit performed better with a 
much higher yield of DNA. A reagent in the Qiagen kit was most likely contaminated, and 
the Promega kit was used for all subsequent DNA extractions.  
 
      L         13     14      15     16      17     18     19    20        
    L        1         2         3        4         5        6       7        8          9      10    11     12 
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Figure 4.10.2.35. DNA extraction using Qiagen kit (1-5) and Promega kit (6-10) 
 
 
 
4.10.3. Restriction Digests 
 
Many restriction digests were carried out in an attempt to determine if fragment 1 had been 
successfully ligated into pCR-Blunt. Fragment 1 should have been completely cut from pCR-
Blunt when Stu1 was used, leaving two bands, one approximately 3.5kb and one at 
approximately 1.0kb. 
 
Figure 4.10.3.16 shows the results of pCR-Blunt-fragment1 post restriction with EcoR1. Cut 
fragment 1 should be 1kb in size. The sample which ran in lane 2 had a band at 1.0kb, which 
is the correct size for fragment 1. The band was purified from the gel and an aliquot sent for 
sequencing. Sequencing results confirmed this showing a 98% match to fragment 1. None of 
the other nine samples showed the isolated fragment in the gel. 
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                      Figure 4.10.3.16. Restriction digests of pCR-Blunt-fragment1 using EcoR1 
 
 
 
At this stage we had successfully PCR amplified fragment 1, ligated it to pCR-Blunt, 
transformed it, extracted the plasmid DNA and purified the fragment. The next step was to 
ligate it to pBacpak8-fragment2.  
 
 
4.10.4. Fragment 2 
 
Although fragment 2 had previously been cloned successfully into pBacPak8, attempts to re-
isolate the fragment before it was ligated to fragment 1 using the restriction enzymes Stu1 
and Kpn1 were unsuccessful.  
Figure 4.10.4.17 shows 14 pBacPak8-fragment2 samples run on a 2% agarose gel. 
Samples were digested using Stu1 and Kpn1. The expected 5.5kb plasmid and 0.8kb 
fragment were not present in any of the samples on the gel. Either no cutting or non-specific 
cutting was observed. From the gel shown in figure 3.5.5, Ssamples 8, 10, 11 and 14 were 
sent for sequencing as these bands appeared the sharpest on the gel. .  
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Figure 4.10.4.17. pBacPak8-fragment2 post Stu1, Kpn1 restriction digest 
 
 All The sequencing results revealed that samples showed slight discrepancies in their 
sequence. These could have been due to random errors or actual errors in the sequence. 
Before a mutagenesis could be performed to correct the error, we had to be certain that the 
pBacPak8-fragment2 sample being used showed no errors in its sequence.  
Sample number 8 (Fig. 3.5.9?? what figure??) was re-sent for sequencing using 
different primers to take a closer look at it. The primers used were: Polyhedrin (PH) and 
Sh176 (diluted 1:10).  
 
Sequencing results showed that fragment 2 was present in pBacPak8, however 
restriction digests were unsuccessful because primers supplied by the company were 
incorrect. The forward primer used when amplifying fragment 2 contained a Stu1 restriction 
site which was incorrect (Fig. 4.10.4.28), and resulted in pBacPak8-fragment2 being 
linearised instead of completely cut. The Stu1 site should have read: 5’...AGGCCT...3’. 
However, the sequence our plasmid read was:  5’...AGCCCT...3’ 
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GCCCCGGGTTTTCGGTACAGCCCTTTAAAAGTACAAACGACACTGATGCTGTGTGAAAAGGA
CAGCAGAAGCACTAAAGCTTTCCCAGAATTTCTTACAGTGGCTTTCTGCTGATCCCACTGAA
CAGATTGCTGTATTCTGTCCTTCCTCCGTCTGTTGCCAATGAGCTGCGGCACAAGCGTCCAG
TGCCTGCCAAAAGATATGACAATGTGACCATCCTCTTTAGTGGCATTGTGGGCTTCAATGCT
TTCTGTAGCAAGCATGCATCTGGAGAAGGAGCCATGAAGATCGTCAACCTCCTCAACGACCT
CTACACCAGATTTGACACACTGACTGATTCCCGGAAAAACCCATTTGTTTATAAGGTGGAGA
CTGTTGGTGACAAGTATATGACAGTGAGTGGTTTACCAGAGCCATGCATTCACCATGCACGA
TCCATCTGCCACCTGGCCTTGGACATGATGGAAATTGCTGGCCAGGTTCAAGTAGATGGTGA
ATCTGTTCAGATAACAATAGGGATACACACTGGAGAGGTAGTTACAGGTGTCATAGGACAGC
GGATGCCTCGATACTGTCTTTTTGGGAATACTGTCAACCTCACAAGCCGAACAGAAACCACA
GGAGAAAAGGGAAAAATAAATGTGTCTGAATATACATACAGATGTCTTATGTCTCCAGAAAA
TTCAGATCCACAATTCCACTTGGAGCACAGAGGCCCAGTGTCCATGAAGGGCAAAAAAGAAC
CAATGCAAGTTTGGTTTCTATCCAGAAAAAAATACAGGAACAGAGGAAACAAAGCAGGATGA
TGACTGAGTACCGAGCTCGAATTCCCGGGCGGCCGCTTAATTAATTGATCCGGGTTATTAGT
ACATTTATTAAGCGCTAGATTCTGTGCGTTGTTGATTTACAGACAATTGTTGTACGTATTTT
AATAATTCATTAAAATTTATAATCTTTTGGGGGTGGTATGTTAGAGCGAAAATCAAATGATT
TTCAGCCGTCTTTATATCTGAATTTAAATATTAAATCCTCAATAGAATTTGGTAAAATAAGG
TTTCGATTTAGTTCAACAAGGGTTGTTTTTCCCGAACCGATGGCTGGACTATTCTTAATTGG
ATTTTCGCCTCAAACGCCACAAACCCTGGCCCAATCTTTGGTAGCAAGCATCTAAGCCCTTT
GTCGAATTCGATGGTTTGGTTTGCAATAAAAGTTCCGAACGCTGCCGTTCTCAAAAGAATAG
TA 
 
Figure 4.10.4.28. Sequencing results of sample number 8 pBacPak8-fragment2. Primers used 
were Bac1 and Bac2. The mutated StuI site is marked in red. 
 
 
 
4.10.5. Mutagenesis to correct Stu1 site 
 
Several mutageneses were performed in order to successfully correct the Stu1 restriction site 
in pBacPak8-fragment2. Figure 4.10.5.19 shows a miniprep carried out on a mutagenesis 
product. As can be seen from the gel, a high level of DNA was extracted.   
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Figure 4.10.5.19. Miniprep performed (Promega kit) on DPN1-treated mutagenesis colonies 
 
 
Mutagenesis samples were then restricted using Stu1. Figure 4.10.5.210 shows the 
restriction results of this restriction. Lanes 2, 4 and 7 (blue arrow) contain fragment 2 (0.8kb) 
with the corrected Stu1 site, indicating that the mutagenesis was successful.  
 
                      
 
Figure 4.10.5.210. Restriction digest (Stu1, Kpn1) performed on mutagenesis/DPN1-treated 
pBacPak8-fragment2 products.  
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4.10.6. Joining of Fragments 1 and 2 
 
Fragment 1 had been successfully cloned into pCR-Blunt, cut and isolated into its 1kb 
fragment. The Stu1 site in pBacPak8-fragment2 had been corrected, and the next step of 
restricting and joining the fragments could begin.   
 
Figure 4.10.6.111 shows the results of a transformation to try to achieve the highest amount 
of DNA possible before ligation of the 2 fragments. Wells 1-5 contain pCR-Blunt-fragment1 
DNA and wells 6-10 contain pBacPak8-fragment2 DNA. 
 
 
 
 
Figure. 4.10.6.111. 2% agarose gel of a miniprep performed on pCR-Blunt-fragment1 and 
pBacPak8-fragment2. pCR-Blunt-fragment1 is 4.3kb therefore runs further on the gel than 
pBacPak8-fragment2 (6.3kb).  
 
Before the ligation was performed, Fragment 1 was isolated and pBacPak8-fragment2 
was linearised using Stu1. An aliquot of fragment 1 and linearised pBacPak8-fragment2 was 
run on a 2% agarose gel to ensure that, both fragments were present, had been cut and were 
the correct size (Fig. 4.10.6.212). As can be seen from the gel, fragment 1 is present at the 
correct size (blue arrow), and linearised pBacPak8-fragment2 is present in lane 2.  
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Figure 4.10.6.212. Lane one shows fragment 1 cut with Stu1. The fragment can be seen at the 
1kb mark (blue arrow). Lane 2 contains pBacPak8-fragment 2 cut and linearised using Stu1. 
As there is a lot more vector present than fragment 1, the vector was diluted 1:5 before the 
ligation was carried out.  
 
 
4.10.7. Restriction digest of pCR-Blunt-fragment1 and pBacpak8-fragment2 
 
Fig 4.10.7.113 shows the restriction digest of pCR-Blunt-fragment1 and pBacpak8-fragment2 
using Stu1. pBacPak8-fragment2 should become linearised (lane 2) and pCR-Blunt-
fragment1 should be completely cut leaving pCR-Blunt and fragment 1 (lane 1). A small 
band at approximately 1kb can be seen in the gel (lane 1), indicating cutting did take place. 
The gel also shows cut and uncut pCR-Blunt.  
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Figure 4.10.7.113 pCR-Blunt-fragment1 and pBACPak8-fragment2 cut with new batch of 
Stu1 enzyme.  
 
 
The results of the restriction digest of fragment 1 and pBacPak8-fragment2 should yield a 
fragment approximately 1.8kb in size, and another fragment 5.5kb in size. This is what was 
expected in Fig. 4.10.7.214. Seventeen colonies which in theory contained the pBacPak-A307 
splice form, were selected and underwent a restriction digest using the enzymes EcoRV and 
Not1. Samples 6, 8, 9, and 13 showed a small fragment, but the size appeared to be nearer the 
1kb mark, rather than 1.8kb. An aliquot of each was sent for sequencing to make sure.  
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Figure 4.10.7.214. Gel of products post restriction digests using enzymes EcoRV and Not1 
 
 
Results of sequencing showed that our fragment had not been ligated successfully and 
the ligation was repeated. Twenty colonies were once again selected and this time, clone 
number 13 was confirmed by sequence to contain fragment 1 in a reverse orientation. To 
correct this, N13 was cut with Stu1 to isolate fragment 1 and it was then re-ligated to 
linearised pBacPak8-fragment2. Obtained colonies were then analysed using a BgIII/EcoR1 
digest (Fig.4.10.7.315). In colonies containing pBacPak8 with fragment 1 in the proper 
orientation, the restriction produced a 1.5kb fragment as BgIII cuts close to the 5’ end of 
fragment 1 and EcoR1 in the vector after the 3’ of fragment 2. The correct clone was 
identified and the laboratory is in the process of confirming SH-β1 ORF incorporated into 
pBacPak8 by sequencing.  
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Figure 4.10.7.315. Restriction digest performed on pBacPak8 containing fragment 1 and 
fragment 2 using the enzymes BgIII and EcoR1. A correct alignment of fragment 1 yields a 
fragment 1.5kbs in length. A reverse alignment of fragment 1 yields a fragment 0.8kbs in 
length.  
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5.0. Discussion 
 
 Evidence that sGC activity is regulated both at the protein and mRNA level has begun 
to emerge over the past few years. However the transcriptional regulation of the expression of 
sGC has not been previously examined. Relatively little is known about the genes or the 
promoter region of mammalian sGC (Sharina et al., 2000). In our study, transcript numbers of 
α1 and β1 subunits of sGC in primary cells were affected by treatment with pro-inflammatory 
cytokines GM-CSF and IL-4. Changes in the mRNA expression levels of sGC subunits have 
been reported in several disease models. In aortic tissue from spontaneously hypertensive 
rats, the vasodilator response to an NO donor was markedly attenuated compared with 
normotensive rats. The detailed analysis of hypertensive animals revealed that α1 and β1 sGC 
mRNA levels, as well as β1 sGC protein levels, were reduced significantly, indicating that 
vasodilator dysfunction is related to the sGC gene expression (Jiang et al., 2006).  
 
We hypothesised that primary endothelial and smooth muscle cells would respond to 
treatment with cytokines which would have an effect on sGC production. Vascular cells are 
both a target for and a source of cytokines (Mantovani et al., 1992). It has been suggested that 
the vasculature, when exposed to inflammatory mediators can adapt to elevated NO levels by 
decreasing the NO receptor sGC. Cytokine-mediated changes in the function of other 
components of the NO-cGMP signal transduction system, such as phosphodiesterases and 
cGMP-dependent protein kinase, may also have important roles in regulating vascular 
responsiveness to NO. Relatively little is known about the effects of cytokines on sGC, but it 
has been demonstrated that α1 and β1 sGC mRNA levels are regulated by inflammatory 
cytokines (Papapetropoulos et al., 1996). Cytokine-induced desensitisation of vascular 
responsiveness to NO may represent a homeostatic mechanism preventing excessive 
signalling via cGMP and may serve to limit vasodilation (Takata et al., 2001). Previous work 
in our lab had shown that BE2 cells responded to cytokine treatment using GM-CSF and IL-
4. The cytokine treatment caused  a decrease in sGC subunit transcript levels. It was observed 
that these cytokines, used in combination, had the strongest effect on transcript levels of both 
α1 and β1 sGC (Fig. 5.1).  
. 
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The effect of IL-4 & GM-CSF treatment on mRNA levels of α1 & β1 sGC 
subunits in human Neuroblastoma (BE2) cells
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Figure 5.1. Q-PCR analysis of α1 and β1 subunit mRNA steady state levels in BE2 cells. 
Transcript levels vs cytokine treatment (Joanna McCarthy, MPhil thesis, unpublished work)  
 
We wanted to know if this same effect on sGC transcript level would be observed 
using primary cells which would reflect a more in vivo-like response. The promoter regions 
of sGC contain elements which are known to respond to certain cytokines, therefore it was 
hypothesised that cytokines may play a role in the regulation of sGC subunit expression. 
 
HAOSMCs. Cytokines play a role in the regulation of smooth muscle cells. HAOSMCs 
results showed that GM-CSF and IL-4,  when used in combination increase the transcript 
number of α1 sGC significantly in both passages when compared with the control.  The same 
results were observed in the β1 sGC transcript levels. Although passage 5 was not significant, 
transcript levels were still higher than untreated samples. These observations indicate that 
cytokine treatment increased both subunits of the sGC heterodimer in HAOSMCs. This is the 
opposite to what has been reported in the literature (Papapetropoulos  et al., 1996;  Masao et 
al., 2001). It has been reported previously that the exposure of rat SMCs to IL-lβ decreases α1 
mRNA levels and corresponding sGC activity (Papapetropoulos et al., 2006). Tumour 
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necrosis factor-α (TNF-α), alongside IL-1β, was demonstrated to decrease sGC α1 and β1 
mRNA, protein levels and activity in rat pulmonary artery SMCs via NO-independent 
mechanisms (Masao et al., 2001). 17β-estradiol decreased β1 sGC in rat anterior pituitary 
gland, but increased α1 mRNA and protein levels, which leads to the inhibition of sGC 
activity (Cabilla et al., 2006). Most of these studies used different cytokines to the ones used 
in our study, and this may be a possible explanation as to why their results differed to ours. It 
makes sense that cytokines would affect cells differently in order to regulate their function. 
Our data demonstrates that α1 and β1 sGC mRNA levels from SMCs are affected by 
inflammatory cytokines, and QPCR experiments analysed the mRNA transcript levels of α1 
and β1 sGC levels to determine if similar effects were seen when the cytokines GM-CSF and 
IL-4 were used.  
 
Transcript levels of α1 vs β1. It was observed that the transcript number of both α1 sGC and β1 
sGC increased in passage 5, compared with passage 4. This indicated that HAOSMCs reach 
an optimum level of proten expression at passage 5. It is known that primary cells in early 
passages express more proteins than repetitively passaged cultures (Cornwell  et al., 1989). It 
may be that smooth muscle cells reach their highest level of sGC expression at passage five. 
Among the sGC subunit isoforms, β1 seems to be the most functionally significant. It is able 
to heterodimerise with both α1 and α2 and in the absence of it, no sGC activity is observed 
(Wagner et al., 2005). β1 has been found expressed ubiquitously in all tissues and so far only 
sGC heterodimers containing β1 have been shown to have catalytic activity in vivo. Decreases 
in β1 expression have been associated with aging, changes in vasodilatory potency, and salt-
sensitivity in rats. Increases in β1 subunit level have been associated with altered vasodilator 
response in aortic rings from rats after myocardial infarction. Expression of the β1 subunit 
was also shown to be developmentally regulated in fish embryos and rat lung and brain 
(Sharina et al, 2003). In both passages, HAOSMCs β1 sGC transcript levels were 
approximately 100 times higher than α1 sGC transcript levels. This could indicate the 
importance of β1 sGC but may also suggest that it has more of a function in the cell than once 
thought. 
 
HAOECs. It has been demonstrated that murine lung vascular endothelial cells can be 
activated in vitro by incubation with IFN-γ and TNF-α (Li  et al., 1991). IL-1 and TNF have 
an array of effects on ECs, and their description occupies a large portion of the literature in 
the area. Recently it was found that ECs express receptors for GM-CSF and respond to these 
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cytokines with migration and proliferation. GM-CSF has been reported to induce expression 
of adhesion structures such as ICAM-1 weakly, and to have angiogenic activity. IL-4 has 
emerged recently as a modulator of EC function, favouring the selective recruitment and 
activation of lymphocytic and monocytic elements crucial for inflammation and immune 
reactions (Mantovani et al., 1992). Unlike appropriate reference cytokines (IL-1, TNF-α, 
IFN-γ), GM-CSF is not known to modulate endothelial cell functions related to haemostasis, 
thrombosis or inflammation. Various cell types, including activated immunocompetent cells, 
fibroblasts, and endothelial cells themselves, can produce GM-CSF. Thus, locally produced 
GM-CSF could be part of the regulatory network of neovascularisation and, in bone marrow, 
contribute to the maintenance of the hematopoietic microenvironment, of which endothelial 
cells are one important component (Bussolino et al., 1991). 
 
Treatment of HAOECs with pro-inflammatory cytokines yielded results which were 
the opposite to that seen in HAOSMCs. In passage 5, the combination of GM-CSF and IL-4 
resulted in a significant decrease in both α1 and β1 sGC transcript levels compared with the 
controls. GM-CSF at 10ng/ml and 50ng/ml had no effect on transcript levels. Passage 6 
results were not significantly different from control. This was more than likely due to the 
cells beginning to decrease their protein expression as they age. Transcript levels of both α1 
and β1 in passage 6 dropped by over 50%. This result was not surprising but culturing to 
passage 6 was needed in order to ensure the cells were confluent enough before treatment. 
Interestingly, although overall passage 6 transcript levels dropped compared with passage 5, 
the samples treated with the combination of cytokines did not undergo the same drop as the 
control samples and those treated with just GM-CSF. Transcript levels remained similar to 
the levels observed in passage 5. The reason for this is unclear.  
 
HAOSMCs/HAOECS  
In our study, HAOECS expressed much higher levels of α1 sGC than HAOSMCs. Up 
to 30 times more. Both primary cell lines express more β1 sGC than α1 sGC. As one subunit 
of each combine to form the sGC heterodimer, this leaves a surplus of β1 sGC which remains 
as a single subunit. This could be a further indication that β1 sGC may have other functions in 
the cell. 
 
The differences in transcript numbers between passages was much greater in 
HAOECs, compared with HAOSMCs Primary cultured aortic smooth muscle cells in later 
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passages (8-10) have been shown not to express enzymes such as cGMP-dependent protein 
kinase, which can be detected using Western Blot analysis in earlier cell passages (Cornwell 
TL et al., 1989). Similarly, it has been reported that myosin is lost is cultured smooth muscle 
cells as part of the process of phenotypic modulation (Rovner  et al., 1986).Various disease 
states are thought to involve decreased expression of sGC. For example, models of 
hypertension, atherosclerosis, and Alzheimer’s disease all correlate with decreased levels of 
sGC (Krumenacker et al., 2005). 
 
Previous QPCR experiments performed on BE2 cells involving GM-CSF and IL-4 
treatment resulted in an increase in both α1 and β1 sGC transcript numbers. HAOECS showed 
the same response with cytokines treatment. As primary cells are difficult to culture 
successfully, and are prone to contamination, BE2 cells could possibly be used as a model to 
study the regulation of sGC mRNA levels in ECs.  
 
 Our laboratory had a large selection of anti α1 and anti β1 sGC antibodies. Some were 
bought commercially, some had been purified in the laboratory and others were different 
boosts of the same antibody. BE2 and Sf9 cells were routinely used in Western blot analysis 
as they express high levels of sGC. With the various antibodies available in the laboratory, an 
evaluation on the quality and specificity of each antibody had never been carried out. As it 
was planned to use an anti α1 and an anti β1 antibody from the laboratory selection on our 
primary cell sample, we first had to determine which antibody performed the best. The 
performance of most of the antibodies was disappointing, with very few showing any 
specificity and binding to random bands on the blots. One anti α1 and one anti β1 antibody 
were chosen for use on our primary cells. It was surprising how badly most of the antibodies 
performed considering they were purified to be specific for sGC. The results of this antibody 
evaluation meant that the laboratory no longer used some of the companies which provided 
these antibodies. 
Western blots were performed on primary cell samples as a method to mirror the 
results obtained from the QPCR data. It was not known before this study if our primary cells 
would express sGC at adequate levels for detection by our chosen α1 and β1 sGC antibodies. 
As was determined from Western blots performed on these samples, overall protein sGC 
levels were too low to detect clear bands on the blots. QPCR results showed that in both cell 
types, β1 sGC transcript numbers were higher than α1 sGC transcript numbers. 50ng/ml GM-
CSF and GM-CSF in combination with IL-4 affected protein levels of β1 sGC in SMCs 
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passage 5, showing clear distinct bands on the blot. No band for α1 sGC was detected. It 
appears that the sGC subunits are not expressed at a high enough level to be detected using 
Western blot analysis, however there is a small possibility that the β1 sGC subunit can be 
detected using appropriate antibodies. This would require further investigation.  
 
 
 Alternative splicing frequently occurs in eukaryotic genes and provides an important 
mechanism for tissue-specific and developmental regulation of gene expression. Several 
reports have suggested that splicing may also be a method of sGC regulation (Sharina et al., 
2000). RT-PCR of sGC mRNA levels have indicated that there is an abundance of splice 
forms in different human tissues (Sharina et al., 2007). The β1 sGC splice variant A307838 
has previously been discovered in the human brain.  
In this project, we aimed to clone A307838 into the expression vector pBacpak8 so 
that eventually it could be expressed in a viral vector to functionally characterise it, and prove 
its biological significance. A307868 was separated into two fragments. Fragment 1 had 
previously been isolated and PCR amplified with Stu1 restriction sites added to both ends. 
Attempts were made to ligate fragment 1 to the vector pCR-Blunt and then transform it into 
competent E. Coli cells. This process took time to optimise and perfect. After several 
attempts, a newly ordered Stu1 enzyme and a newly evaluated DNA extraction kit, fragment 
1 was successfully ligated to pCR-Blunt, and transformed into competent cells. Cultured cells 
then underwent restriction digests and fragment 1 was found to be present.  
 Initial attempts to ligate fragment 1 with fragment 2 (already ligated to pBacPak8) 
were unsuccessful due to it being discovered that company-produced primers had been 
synthesised incorrectly leading to inaccurate or no cutting of the enzyme Stu1. New primers 
were designed in an attempt to correct this restriction site and several mutageneses were 
performed.  Once pBacpak8-fragment2 had been corrected it was restricted and ligated to 
fragment 1. Initial attempts were unsuccessful, with isolated fragments being of an incorrect 
size. Eventually fragment 1 was successfully ligated to pBacPak8-fragment2, however, it was 
discovered that it had been ligated backwards. There was a 50% chance of this occurring, but 
it was hoped that enough colonies would be grown to ensure at least one was correct. 
Unfortunately this was not the case, and attempts continue in the laboratory to achieve the 
successful ligation and correct orientation of fragment 1 to fragment 2. 
The function and biological significance of A307838 is still unknown.  A functional 
β1 sGC splice variant has never previously been identified, and it is hoped that with further 
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research and kinetic and enzymatic studies, A307838 will be found to play an important role 
in regulation and expression of sGC.  
 
 
166 
 
6.0. Conclusion 
 
Considering the importance of the function of sGC, and the reports concerning the 
functional significance of the splice variants for both subunits, our results should help to gain 
insights into the genetic basis of regulation of this important enzyme.  
 
From the QPCR results we can conclude that the effect of cytokine regulation of 
transcription is highly dependent on cell type. In HAOSMCs, the coordination of 
transcription levels between α1 and β1 genes is indicative of synchronised activity of the 
promoters. In HAOECs, gene expression changes with each passage. The response of 
HAOECs to cytokine treatment is a similar response in BE2 cells, which validates BE2 as a 
model to study the regulation of sGC mRNA levels in HAOEC but not HAOSMCs. QPCR 
results from both cells types indicate that β1 sGC may have further functions in the cell in 
addition to dimerisation with α1.  
 
We can conclude from our Western results that in general, protein levels from 
HAOSMC and HAOECs are too low to yield usable blots. For our HAOSMCs at passage 4, 
both combination of GM-CSF and IL4 affect protein and mRNA levels of β1 sGC. But high 
concentrations of GM-CSF affect only protein levels, implicating post-transcriptional 
regulation.  
 
In summary, this study identifies the effects of GM-CSF and IL-4 on sGC expression 
in primary cells. Our findings point to a role of cytokines in the regulation and activity of 
sGC subunits.  It suggests that regulation may be finely tuned and may have significant 
effects on nitric oxide and cyclic GMP signalling.  
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